Anti-TL1a x Anti-il23 antibodies

Abstract

Provided herein are novel anti-TLl A antibodies. anti-IL23 antibodies, and anti-TLIA x anti-IL23 antibodies and methods of using such antibodies for the treatment of TL1 A- and IL23 -associated diseases (e.g., inflammatory diseases).

Description

Attorney Docket No. 078306 / 636740ANTI-TL1A X ANTI-IL23 ANTIBODIESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of US Application No. 63 / 692,669, filed September 9, 2024, US Application No. 63 / 761,754, filed February721, 2025, and US Application No. 63 / 796,313, filed April 28, 2025, each of which is herein incorporated by reference in its entirety for all purposes.REFERENCE TO A SEQUENCE LISTING SUBMITTED AS AN XML FILE

[0002] The Sequence Listing written in file 636740SEQLIST.xml is 2,599,626 bytes, was created on September 9, 2025, and is hereby incorporated by reference in its entirety.BACKGROUND

[0003] Antibody-based therapeutics have been used successfully to treat a variety of diseases. There remains a need for novel therapeutics for the treatment of diseases, particularly those that target TNF-like ligand 1 A (TL1 A) and / or IL23.SUMMARY

[0004] Provided herein are novel anti-TLIAx anti-IL23 antibodies and methods of using such antibodies for the treatment of TL1A- and / or IL23-associated diseases. Also provided are novel anti-TLl A antibodies and methods of using such antibodies for the treatment of TL1 A- associated diseases, novel anti-IL23 antibodies and methods of using such antibodies for the treatment of IL23-associated diseases, and combinations of anti-TLl A antibodies and anti-IL23 antibodies and methods of using such antibodies for the treatment of TL1A- and / or IL23 -associated diseases.

[0005] In one aspect provided herein is a bispecific anti-TNF-like ligand 1 A (TL1A) x antiinterleukin-23 (IL23) bispecific antibody comprising: a) a means for binding TL1 A; and b) a means for binding IL23.

[0006] In another aspect provided herein is a bispecific anti-TLIAx anti-IL23 antibody comprising: a) a TL1 A binding domain comprising i) a first variable heavy domain (VH1), and ii) a first variable light domain (VL1); and b) a IL23 binding domain comprising i) a second variable heavy domain (VH2), and ii) a second variable light domain (VL2). In someAttorney Docket No. 078306 / 636740 embodiments the TL1 A binding domain comprises the VH and VL of any of the TL1 A binding domains in Tables 7-10. In some embodiments, the IL23 binding domain comprises the VH and VL of IL23-A[IL23]_H1L1 (Table 11).

[0007] In another aspect, provided herein is a heterodimeric antibody that comprises: a) a first monomer; b) a second monomer; and c) a light chain. The first monomer comprises: i) a single chain variable fragment (scFv); and ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker. The second monomer comprises, fromN-terminal to C-terminal, a VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a second Fc domain. The light chain comprises, from N-terminal to C- terminal, VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain. The scFv comprises a second VH domain (VH2), a scFv linker, and a second variable light domain (VL2). Further, the VH1 and the VL1 together form a first antigen-binding domain (ABD) and the VH2 and the VL2 together form a second ABD. and one of the first ABD and second ABD is a TL1 A binding domain and the other of the first ABD and second ABD is a IL23 binding domain.

[0008] In some embodiments, the scFv comprises, from N-terminal to C-terminal, VH2-scFv linker-VL2. In other embodiments, the scFv comprises, from N-terminal to C-terminal, VL2- scFv linker- VH2.

[0009] In some embodiments, the first ABD is the TL1A binding domain and the second ABD is the IL23 binding domain. In some embodiments, the first ABD is the IL23 binding domain and the second ABD is the TL1 A binding domain. In some embodiments, the TL1 A binding domain comprises the VH and VL of any of the TL1 A binding domains in Tables 7- 10. In certain embodiments, the IL23 binding domain comprises the VH and VL of 1L23- A[IL23]_H1L1 (Table 11).

[0010] In another aspect, provided herein is a heterodimeric antibody that comprises: a) a first monomer; b) a second monomer; c) a first light chain; and d) a second light chain. The first monomer comprises a VHl-CHl-hinge-CH2-CH3. wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain. The second monomer comprises a VH2-CH1- hinge-CH2-CH3, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain. The first light chain comprises a VL1-CL, wherein VL1 is a first variable light domain. The second light chain comprises a VL2-CL. wherein VL2 is a second variable light domain. The VH1 and the VL1 together form a first antigen-binding domain (ABD) and the VH2 and the VL2 together form a second ABD. One of the first ABD and second ABD is aAttorney Docket No. 078306 / 636740TL1 A binding domain and the other of the first ABD and second ABD is a IL23 binding domain. Further, i) CHI of the first monomer and CL1 of the first light chain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27 or a set of steric skew variants as depicted in Figure 5 or Table 28; ii) VH1 of the first monomer and VL1 of the first light chain comprise a set of electrostatic steering variants as depicted in Figure 6 or Tables 18 and 19; iii) CHI of the second monomer and CL1 of the second light chain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27 or a set of steric skew variants as depicted in Figure 5 or Table 28; and / or iv) VH2 of the second monomer and VL2 of the second light chain comprise a set of electrostatic steering variants as depicted in Figure 6 or Tables 18 and 19.

[0011] In some embodiments, the CHI of the first monomer and CL1 of the first light chain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27. In some embodiments, the CHI of the first monomer and CL1 of the first light chain comprise a set of steric skew variants as depicted in Figure 5 or Table 28. In exemplary embodiments, the VH1 of the first monomer and VL1 of the first light chain comprise a set of electrostatic steering variants as depicted in Figure 6 or Tables 18 and 19. In some embodiments, the CHI of the second monomer and CL1 of the second light chain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27. In some embodiments, the CHI of the second monomer and CL1 of the second light chain comprise a set of steric skew variants as depicted in Figure 5 or Table 28. In exemplary embodiments, the VH2 of the second monomer and VL2 of the second light chain comprise a set of electrostatic steering variants as depicted in Figure 6 or Tables 18 and 19.

[0012] In some embodiments. VH1 comprises amino acid substitution Q39E and VL1 comprises amino acid substitution Q38K (Kabat numbering). In some embodiments, VH1 comprises amino acid substitution Q39K and VL1 comprises amino acid substitution Q38E (Kabat numbering). In exemplary embodiments, VH1 comprises Q39E, VL1 comprises Q38K, VH2 comprises Q39K and VL2 comprises Q38E (Kabat numbering).

[0013] In some embodiments, CH 1 of the first monomer comprises amino acid substitutions K213E / K218D and CL comprises amino acid substitutions D122K / E123K (EU numbering). In some embodiments, CHI of the first monomer comprises amino acid substitutions A141F and CL comprises amino acid substitution F118A (EU numbering). In exemplary embodiments, CHI of the first monomer comprises amino acid substitutions K213E / K218D, CL of the first light chain comprises amino acid substitutions D122K / E123K, CHI of theAttorney Docket No. 078306 / 636740 second monomer comprises amino acid substitutions A141F and CL of the second light chain comprises amino acid substitution F118A (EU numbering).

[0014] In some embodiments, VH1 comprises amino acid substitution Q39E (Kabat numbering), VL1 comprises amino acid substitution Q38K (Kabat numbering), CHI of the first monomer comprises amino acid substitutions K213E / K218D (EU numbering), CL of the first light chain comprises amino acid substitutions D122K / E123K (EU numbering), VH2 comprises amino acid substitution Q39K (Kabat numbering), VL2 comprises amino acid substitution Q38E (Kabat numbering), CHI of the second monomer comprises amino acid substitutions A141F (EU numbering) and CL of the second light chain comprises amino acid substitution Fl 18A (EU numbering).

[0015] In exemplary embodiments, the first ABD is the TL1 A binding domain and the second ABD is the IL23 binding domain. In some embodiments, the first ABD is the IL23 binding domain and the second ABD is the TL1 A binding domain. In certain embodiments, the TL1 A binding domain comprises the VH and VL of any of the TL1 A binding domains in Tables 7- 10. In some embodiments, the IL23 binding domain comprises the VH and VL of IL23- A[IL23]_H1L1 (Table 11).

[0016] In another aspect provided herein is a heterodimeric antibody comprising: a) a first monomer; b) a second monomer; c) a first common light chain; and d) a second common light chain. The first monomer comprises a VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain. The second monomer comprises a VH2-CHl-hinge-CH2-CH3, wherein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain. Each of the first and second common light chains comprise a VL-CL. The VH1 and the VL of the first common light chain together form a first antigen-binding domain (ABD) and the VH2 and the VL of the second common light chain together form a second ABD.

[0017] In some embodiments, the first ABD is the TL1 A binding domain and the second ABD is the IL23 binding domain. In other embodiments, the first ABD is the IL23 binding domain and the second ABD is the TL1A binding domain.

[0018] In some embodiments, the TL1 A binding domain comprises the VH and VL of any of the TL1 A binding domains in Tables 7-10. In some embodiments, the IL23 binding domain comprises the VH and VL of IL23-A[IL23]_H1L1 (Table 11).

[0019] In another aspect, provided herein is a heterodimeric antibody that comprises: a) a first monomer; b) a second monomer; c) a first light chain; and d) a second light chain. TheAttorney Docket No. 078306 / 636740 first monomer comprises: i) a VHl-CHl-hinge-CH2-CH3, and ii) a first scFv comprising a VH2-scFv linker-VL2, wherein the scFv is covalently attached to the CH3 of the first monomer by a linker. The second monomer comprises: i) a VHl-CHl-hinge-CH2-CH3, and ii) a second scFv comprising a VH2-scFv linker-VL2. wherein the scFv is covalently attached to the CH3 of the second monomer by a linker. Each of the first and second light chains comprise a VL1 -CL. Each of the VHls of the first monomer and second monomer are a first variable heavy domain, each of the VLls of the first monomer and second monomer are a first light domain, each of the VH2s are a second variable heavy domain, and each of the VL2s are a second variable light domain. Further, the VH1 of the first monomer and VL1 of the first light chain, and the VH1 of the second monomer and VL1 of the second light chain each form a first antigen-binding domain, and the VH2 and VL2 of the first and second scFvs each for a second antigen-binding domain, wherein the first ABDs or the second ABDs are TL1A binding domains and the other of the first ABDs and second ABDs are IL23 binding domains.

[0020] In some embodiments, the first and second scFvs each comprise, from N-terminal to C-terminal, VH2-scFv linker-VL2. In other embodiments, the first and second scFvs each comprise, from N-terminal to C-terminal, VL2-scFv linker- VH2.

[0021] In some embodiments, the first ABDs are the TL1 A binding domains and the second ABDs are the IL23 binding domain. In other embodiments, the first ABD is the IL23 binding domain and the second ABD is the TL1 A binding domain. In some embodiments, the TL1 A binding domain comprises the VH and VL of any of the TL1 A binding domains in Tables 7- 10. In some embodiments, the IL23 binding domain comprises the VH and VL of IL23- A[1L23]_H1L1 (Table 11).

[0022] In some embodiments of the heterodimeric antibodies provided herein, the first Fc domain and second Fc domain are each variant Fc domains. In some embodiments, the first and second Fc domains comprise a set of heterodimerization skew variants selected from the following heterodimerization variants: S364K / E357Q : L368D / K370S; S364K : L368D / K370S; S364K : L368E / K370S; D401K: T411E / K360E / Q362E; and T366W : T366S / L368A / Y407V, wherein numbering is according to EU numbering. In exemplary embodiments, the first and second Fc domains comprise heterodimerization skew variants S364K / E357Q : L368D / K370S, wherein numbering is according to EU numbering.Attorney Docket No. 078306 / 636740

[0023] In some embodiments, the first and second Fc domains each comprise one or more ablation variants. In some embodiments, the one or more ablation variants comprise E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering.

[0024] In some embodiments, one of the first or second monomer further comprises one or more pl variants. In some embodiments, the CHl-hinge-CH2-CH3 of the second monomer comprises pl variants N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering.

[0025] In some embodiments, the CHl-hinge-CH2-CH3 of the second monomer comprises amino acid variantsE233P / L234V / L235A / G236del / S267K / L368D / K370S / N208D / Q295E / N384D / Q418E / N421 D, the first Fc domain comprises amino acid variants E233P / L234V / L235A / G236del / S267K / S364K / E357Q, and wherein numbering is according to EU numbering.

[0026] In some embodiments, the first and second variant Fc domains each comprise amino acid variants 428L / 434S.

[0027] In some embodiments wherein the heterodimeric antibody includes an scFv with an scFv linker, the scFv linker has the amino acid sequence GKPGSGKPGSGKPGSGKPGS (SEQ ID NO: 16).

[0028] Also provided herein are nucleic acid and expression vector compositions encoding the subject antibodies, host cells comprising the expression vector compositions, and methods of making the subject antibodies.

[0029] In another aspect, provided herein is a method of treating a TL1 A-associated and / or IL23 associated disease in a patient in need thereof, comprising administering to the patient a subject anti-TLIA x anti-IL23 antibody described herein.

[0030] In one aspect, provided are bispecific or heterodimeric antibodies comprising: (a) a TLlA-binding domain comprising a first variable heavy domain (VH1) and a first variable light domain (VL1); and (b) an IL23-binding domain comprising a second variable heavy domain (VH2) and a second variable light domain (VL2).

[0031] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 and the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Table 44, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and aAttorney Docket No. 078306 / 636740 vhCDR3 and the VL1 comprises a vlCDRl. a vlCDR2. and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Tables 7-10, 22, 23, 26, 29-34, and 48, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of 1824-1923, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 and VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in Table 44, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the VH1 and VL1 comprise any pair of anti-TLIA variable heavy domain and variable light domain in Tables 7-10, 22, 23, 26, 29-34. and 48, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising the amino acid sequence of any one of 1824-1923, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0032] In some such antibodies, the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 and the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLIA variable heavy domain and variable light domain in Table 44, optionally wherein the CDRs are as defined by the Kabat. Chothia, Kabat + Chothia. AbM, contact, or IMGT definition. In some such antibodies, the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 and the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLIA variable heavy domain and variable light domain in Tables 11, 24-26, 29- 34, and 49. optionally wherein the CDRs are as defined by the Kabat. Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of 1927-2132, and the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of 2133-2232, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, theAttorney Docket No. 078306 / 636740VH2 and VL2 comprise any pair of anti-lL23 variable heavy domain and variable light domain in Table 44 or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the VH2 and VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in Tables 11, 24-26, 29-34, and 49 or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising the amino acid sequence of any one of 1927-2132, and a variable light domain comprising the amino acid sequence of any one of 2133-2232 or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0033] In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl. a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a v ariable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1Attorney Docket No. 078306 / 636740 and the VL1 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl. a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 101. and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 109, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 and the VL1 comprise aAttorney Docket No. 078306 / 636740 variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 117, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 125, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 133, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 141, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 149, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 157, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 161, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the aminoAttorney Docket No. 078306 / 636740 acid sequence of SEQ ID NO: 169, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl. a vlCDR2. and a vlCDR3 contained within any pair of anti- TL1A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Tables 29 and 31-34. In any of the above, the CDRs are optionally as defined by the Kabat, Chothia. Kabat + Chothia, AbM, contact, or IMGT definition.

[0034] In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201 , a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the aminoAttorney Docket No. 078306 / 636740 acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 103, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 110, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 111, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 112, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 114. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 115, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 118, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 119, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 120, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 122, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 124. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 126, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 127, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 128, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO: 130. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 131, and a vlCDR3 comprising the amino acid sequence of the amino acid sequence of SEQ ID NO: 132. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 134, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 135. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 136, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 138, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 139, and a vlCDR3 comprising the amino acid sequence of the amino acid sequence of SEQ ID NO: 140. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 142, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 143, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 144, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 146, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 147, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 148. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 150, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 151. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 152. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 154, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 155, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 156. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 118, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 158, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 120, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 122, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 160. In some such antibodies, the VH1 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 162, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 163, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 164, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 166, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 167, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 168. In some such antibodies, the VH1Attorney Docket No. 078306 / 636740 and the VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 170, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 171, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 172, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 174. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 175, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 176.

[0035] In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674. and 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%. at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In someAttorney Docket No. 078306 / 636740 such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1 74, 1200, 1661, and 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 101, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 109, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 117, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 125, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence SEQ ID NO: 133, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 141, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 145. In some such antibodies,Attorney Docket No. 078306 / 636740 the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 149, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 is at least 90%, at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 157, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 161, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 169, and the VL1 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti- TL1A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370. XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in Tables 29 and 31-34.

[0036] In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241. and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises theAttorney Docket No. 078306 / 636740 amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 101, and the VL1 comprises the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 109, and the VL1 comprises the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 117, and the VL1 comprises the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VEH comprises the amino acid sequence of SEQ ID NO: 125, and the VL1 comprises the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 133, and the VL1 comprises the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 141, and the VL1 comprises the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 149, and the VL1 comprises the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 157, and the VL1 comprises the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 161, and the VL1 comprises the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 169, and the VL1 comprises the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 comprise any pair of anti- TL1A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380. or XENP53414. In some such antibodies, the VH1 and the VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in Tables 29 and 31-34. In some embodiments, the VH1 orAttorney Docket No. 078306 / 636740VL1 can compnse variants of any of the above in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0037] In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233. 2235, and 179. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234, 2237. and 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavydomain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavydomain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 and VL2 comprise a variable heavydomain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavydomain comprising the amino acid sequence of SEQ ID NO: 1967, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy- domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412,Attorney Docket No. 078306 / 636740XENP53413, XENP53369, XENP53375, XENP53387. XENP53415. XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In any of the above, optionally the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia. AbM, contact, or IMGT definition.

[0038] In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.

[0039] In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ IDAttorney Docket No. 078306 / 636740NOS: 2234, 2237, and 1248. In some such antibodies, the VH2 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113. and the VL2 is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231 . In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 and the VL2 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387. XENP53415, XENP53370, XENP53371, XENP53376, XENP53377. XENP53378. XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and the VL2 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in Table 29 or 33.

[0040] In some such antibodies, the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248. In some such antibodies, the VH2 comprises theAttorney Docket No. 078306 / 636740 amino acid sequence of SEQ ID NO: 2233, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 1967, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387. XENP53415, XENP53370, XENP53371, XENP53376, XENP53377. XENP53378. XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in Table 29 or 33. In some such antibodies, the VH2 or VL2 can comprise variants of any of the above in which an N- terminal glutamine or glutamate is replaced with pyroglutamate.

[0041] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. (hi) the VH2 comprises a vhCDRl. a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and aAttorney Docket No. 078306 / 636740 vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (lii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, (ii) the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, (iii) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-l l M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1 A with a KD of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1A activity in a TL1 A luciferase reporter assay with an ICso of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M. or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an ICso of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an ICso of less than about 60 pM, less than about 59 pM. less than about 58 pM. less than about 57 pM. or less than about 56 pM.

[0042] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2Attorney Docket No. 078306 / 636740 comprises a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 compnsing the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241 , (ii) the VL 1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a Ko of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E-11 M. less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an ICso of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a Ko of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an ICso of less than about 65 pM, less than about 64 pM. or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity- with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.Attorney Docket No. 078306 / 636740

[0043] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0044] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence ofAttorney Docket No. 078306 / 636740SEQ ID NO: 1201. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0045] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2Attorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234. or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0046] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182. and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0047] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within aAttorney Docket No. 078306 / 636740 variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182. and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence SEQ ID NO: 1200, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0048] In some such antibodies, the bispecific antibody comprises (i) a first heavy chain comprising the VH1 and a first heavy chain constant domain, (ii) a first light chain comprising the VL1 and a first light chain constant domain, (iii) a second heavy chain comprising the VH2 and a second heavy chain constant domain, and (iv) a second light chain comprising the VL2 and a second light chain constant domain. In some such antibodies, the first heavy chain constant domain and the second heavy chain constant domain comprise a set of heterodimerization skew variants. In some such antibodies, the first heavy chain constant domain and the second heavy chain constant domain each comprise one or more ablation variants. In some such antibodies, the first heavy chain constant domain or the second heavychain constant domain comprises one or more pl variants. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy' chain constant domainAttorney Docket No. 078306 / 636740 comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions L368D / K370S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions L368D / K370S, and the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K. M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering, and the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering.Attorney Docket No. 078306 / 636740

[0049] In some such antibodies, the first heavy chain constant domain is of isotype IgGl, and the second heavy chain constant domain is of isotype IgGl. In some such antibodies, the bispecific antibody is a chimeric or humanized bispecific antibody.

[0050] In some such antibodies, the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-l l M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1 A with a KD of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an ICso of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a Kn of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M. or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an ICso of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an ICso of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0051] In another aspect, provided are bispecific or heterodimeric antibodies comprising (a) a first monomer comprising a first heavy chain comprising a VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain, CHl-hinge-CH2-CH3 is a first heavy chain constant domain, and CH2-CH3 is a first Fc domain; (b) a second monomer comprising a second heavy chain comprising a VH2-CHl-hinge-CH2-CH3, wherein VH2 is a second variable domain, CHl-hinge-CH2-CH3 is a second heavy chain constant domain, and CH2- CH3 is a second Fc domain; (c) a first light chain comprising a VL1-CL, wherein VL1 is a first variable tight domain, and CL is a first light chain constant domain; and (d) a second light chain comprising a VL2-CL, wherein VL2 is a second variable light domain, and CL is a second tight chain constant domain, wherein the VH1 and VL1 together form a first antigen-binding domain (ABD), and the VH2 and the VL2 together form a second ABD, wherein the first ABD is a TL1 A-binding domain and the second ABD is an IL23-binding domain, or wherein the first ABD is an IL23-binding domain and the second ABD is a TL1 A- binding domain, and w herein: (i) the first heavy chain constant domain and the first light chain constant domain comprise a set of electrostatic steering variants at positions 213 andAttorney Docket No. 078306 / 636740218 of the first heavy chain constant domain according to EU numbering and positions 122 and 123 of the first light chain constant domain according to Kabat numbering, or a set of st eric skew variants at position 141 of the first heavy chain constant domain according to EU numbering and position 118 of the first light chain constant domain according to Kabat numbering, at position 141 of the first heavy’ chain constant domain according to EU numbering and position 116 of the first light chain constant domain according to Kabat numbering, or at position 147 of the first heavy chain constant domain according to EU numbering and position 131 of the first light chain constant domain according to Kabat numbering; and / or (ii) the VH1 and the VL1 comprise a set of electrostatic steering variants at position 39 of VH1 and position 38 of VL1 according to Kabat numbering; and / or (iii) the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants at positions 213 and 218 of the second heavy chain constant domain according to EU numbering and positions 122 and 123 of the second light chain constant domain according to Kabat numbering, or a set of steric skew variants at position 141 of the second heavy chain constant domain according to EU numbering and position 118 of the second light chain constant domain according to Kabat numbering, at position 141 of the second heavy chain constant domain according to EU numbering and position 116 of the second light chain constant domain according to Kabat numbering, or at position 147 of the second heavy chain constant domain according to EU numbering and position 131 of the second light chain constant domain according to Kabat numbering; and / or (iv) the VH2 and the VL2 comprise a set of electrostatic steering variants at position 39 of VH2 and position 38 of VL2 according to Kabat numbering. For example, any of the above antibodies can be in this format.

[0052] In some such antibodies, the first heavy chain constant domain and the first light chain constant domain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27 or a set of steric skew variants as depicted in Figure 5 or Table 28. In some such antibodies, the VH1 and the VL1 comprise a set of electrostatic steering variants as depicted in Figure 6 or Table 18 or 19. In some such antibodies, the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27 or a set of steric skew variants as depicted in Figure 5 or Table 28. In some such antibodies, the VH2 and the VL2 comprise a set of electrostatic steering variants as depicted in Figure 6 or Table 18 or 19.Attorney Docket No. 078306 / 636740

[0053] In some such antibodies, the VH1 comprises amino acid substitution Q39E and the VL1 comprises amino acid substitution Q38K according to Kabat numbering. In some such antibodies, the VH2 comprises amino acid substitution Q39K and the VL2 comprises amino acid substitution Q38E according to Kabat numbering. In some such antibodies, the VH1 comprises amino acid substitution Q39E, the VL1 comprises amino acid substitution Q38K, the VH2 comprises amino acid substitution Q39K, and the VL2 comprises amino acid substitution Q38E according to Kabat numbering.

[0054] In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering, and the first light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering. In some such antibodies, the second heavy chain constant domain comprises amino acid substitution A141F according to EU numbering, and the second light chain constant domain comprises amino acid substitution F118A according to Kabat numbering. In some such antibodies, (a) the VH1 comprises amino acid substitution Q39E. the VL1 comprises amino acid substitution Q38K, the VH2 comprises amino acid substitution Q39K, and the VL2 comprises amino acid substitution Q38E according to Kabat numbering; (b) the first heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering, and the first light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering; and (c) the second heavy chain constant domain comprises amino acid substitution A141F according to EU numbering, and the second light chain constant domain comprises amino acid substitution F118A according to Kabat numbering.

[0055] In some such antibodies, the first ABD is a TLlA-binding domain and the second ABD is an IL23 -binding domain.

[0056] In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241. 2253, 2259, 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within aAttorney Docket No. 078306 / 636740 variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a v hCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674. and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising a vlCDRl. a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661. and 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence ofAttorney Docket No. 078306 / 636740SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 compnse a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 101, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 109, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 117, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained ithin a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 125, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 133, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 141, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and aAttorney Docket No. 078306 / 636740 vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 149, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 157, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 161, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1 9, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378. XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti- TLl A variable heavy domain and variable light domain in Tables 26 and 29-34. Optionally, the CDRs in any of the above antibodies are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

[0057] In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2Attorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO: 107. and a vlCDR3 compnsing the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 103, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acidAttorney Docket No. 078306 / 636740 sequence of SEQ ID NO: 110. a vhCDR2 compnsing the amino acid sequence of SEQ ID NO: 111, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 112, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 114, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 115, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 118, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 119, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 120, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 122, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 124. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 126, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 127. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 128. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 130, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 131, and a vlCDR3 comprising the amino acid sequence of the amino acid sequence of SEQ ID NO: 132. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 134, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 135, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 136, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 138, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 139. and a vlCDR3 comprising the amino acid sequence of the amino acid sequence of SEQ ID NO: 140. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 142, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 143, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 144. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 146, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 147, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 148. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 150, a vhCDR2 compnsing the amino acid sequence of SEQ ID NO: 151, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 152, and aAttorney Docket No. 078306 / 636740 variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 154, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 155, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 156. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 118. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 158, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 120, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 122, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 160. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 162, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 163, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 164, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 166. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 167, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 168. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 170, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 171. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 172. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 174, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 175, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 176.

[0058] In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, theAttorney Docket No. 078306 / 636740VH1 is at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%, at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1824- 1923. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 101, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 109, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acidAttorney Docket No. 078306 / 636740 sequence of SEQ ID NO: 113. In some such antibodies, the VH1 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 117, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 125, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence SEQ ID NO: 133, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 141, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 149, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 157, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 161, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 169, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti- TL1 A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371,Attorney Docket No. 078306 / 636740XENP53376, XENP53377, XENP53378, XENP53379. XENP53380. or XENP53414. In some such antibodies, the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in Tables 26 and 29-34.

[0059] In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2323. and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 101, and the VL1 comprises the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 109, and the VL1 comprises the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 117, and the VL1 comprises the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 125, and the VL1 comprises the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 133, and the VL1 comprises the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 comprises theAttorney Docket No. 078306 / 636740 amino acid sequence of SEQ ID NO: 141. and the VL1 comprises the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 149, and the VL1 comprises the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 157, and the VL1 comprises the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 161, and the VL1 comprises the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 169, and the VL1 comprises the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 comprise any pair of anti- TL1 A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH1 and the VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in Tables 26 and 29-34. In some such antibodies, the VH1 or VL1 can comprise variants of any above the above in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0060] In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a vanable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domainAttorney Docket No. 078306 / 636740 comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 183. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl. a vlCDR2. and a vlCDR3 contained within any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-IL23 variable heavy domain and variable light domain in Tables 26 and 29-34. In some such antibodies, optionally the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

[0061] In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2Attorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO: 181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 115, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 185.

[0062] In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ IDAttorney Docket No. 078306 / 636740NOS: 2234, 2237, and 1248. In some such antibodies, the VH2 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113. and the VL2 is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231 . In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 183. In some such antibodies, the VH2 and the VL2 are at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371. XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and the VL2 are at least 90%, at least 95%, at least 96%, at least 97%, atAttorney Docket No. 078306 / 636740 least 98%, or at least 99% identical to any pair of anti-lL23 variable heavy domain and variable light domain in Tables 26 and 29-34.

[0063] In some such antibodies, the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235. and 179, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 1967. and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 183. In some such antibodies, the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in Tables 26 and 29-34. In some such antibodies, the VH2 or VL2 can comprise variants of any of the above in which an N- terminal glutamine or glutamate is replaced with pyroglutamate.

[0064] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising theAttorney Docket No. 078306 / 636740 amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241 , 2253, 2259, 1674, and 1200, (ii) the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, (iii) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured bysurface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity- in a TL1 A luciferase reporter assay with an ICso of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1. IE-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an ICso of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecificAttorney Docket No. 078306 / 636740 antibody inhibits 1L23 activity with an IC50 of less than about 60 pM. less than about 59 pM. less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0065] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253. and 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233 or 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234 or 2237, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VLl comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, and 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233 or 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234 or 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a Ko of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C. optionally wherein the bispecific antibody specifically binds human TL 1 A with a KD of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1A activity in a TL1AAttorney Docket No. 078306 / 636740 luciferase reporter assay with an IC50 of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a Kn of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0066] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the ammo acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182. and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241. (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, orAttorney Docket No. 078306 / 636740 variants thereof in which an N -terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a Ko of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C. optionally wherein the bispecific antibody specifically binds human TL 1 A with a KD of less than about 3E- 11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an ICso of less than about 65 pM. less than about 64 pM. or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an ICso of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0067] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and (iv)Attorney Docket No. 078306 / 636740 the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241. (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0068] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233. and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.Attorney Docket No. 078306 / 636740

[0069] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234. or vanants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0070] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some suchAttorney Docket No. 078306 / 636740 antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0071] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2Attorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence SEQ ID NO: 1200, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0072] In some such antibodies, the first Fc domain and the second Fc domain comprise a set of heterodimerization skew variants. In some such antibodies, the first Fc domain and the second Fc domain each comprise one or more ablation variants. In some such antibodies, the first monomer or the second monomer comprises one or more pl variants. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions L368D / K.370S. wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, andN208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions L368D / K370S, and the second heavy chain constantAttorney Docket No. 078306 / 636740 domain comprises amino acid substitutions E357Q / S364K. wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy' chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering, and the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering.

[0073] In some such antibodies, the first heavy chain constant domain is of isotype IgGl, and the second heavy chain constant domain is of isotype IgGl. In some such antibodies, the bispecific antibody is a chimeric or humanized bispecific antibody.

[0074] In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2252 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2258 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2252, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the first heavy chain is at least 90%,Attorney Docket No. 078306 / 636740 at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2258, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242.

[0075] In some such antibodies, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2250 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2251. In some such antibodies, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2250, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2251.

[0076] In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1132 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1134, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1133 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1135. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1136 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1138, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1137 or a variant thereof in which the N-terminal glutamine is replaced withAttorney Docket No. 078306 / 636740 pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1139. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1084 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1086, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1085 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1087. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1108 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1110. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1109 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1111. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1088 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1090, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1089 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1091. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1092 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1094, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1093 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1095. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO:Attorney Docket No. 078306 / 6367401112 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1114, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1113 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1115. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1116 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1118, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1117 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1119. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1120 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1122. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1121 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1123. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1124 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1126. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1125 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1127. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1128 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1130, the second heavy chainAttorney Docket No. 078306 / 636740 comprises the amino acid sequence of SEQ ID NO: 1129 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1131. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1140, the first light chain comprises the amino acid sequence of SEQ ID NO: 1142, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1141, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1143. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1132, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1134, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1133, and the second light chain is at least 90%, at least 95%, at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1135. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1136, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1138, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1137, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1139. In some such antibodies, the first heavy chain is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1084, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1086, the second heavy chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1085, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1087. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1108, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at leastAttorney Docket No. 078306 / 63674099% identical to the amino acid sequence of SEQ ID NO: 1110, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1109, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1111. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1088, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1090, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1089, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1091. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1092, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1094, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1093, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1095. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1112, the first light chain is at least 90%, at least 95%, at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1114, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1113, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1115. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1116, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1118, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1117, and the second light chain is at least 90%, atAttorney Docket No. 078306 / 636740 least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1119. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1120, the first light chain is at least 90%, at least 95%, at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1122, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1121, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1123. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1124, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1126, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1125, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1127. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1128, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1130, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1129, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1131. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1140, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1142, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1141, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1143. In some such antibodies, the first heavy chain, the first light chain, the second heavy chain, and the second light chain comprise any set of four chainsAttorney Docket No. 078306 / 636740 from XENP53412. XENP53413, XENP53369, XENP53375, XENP53370. XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the first heavy chain, the first light chain, the second heavy chain, and the second light chain comprise any set of four chains from Tables 29 and 30.

[0077] In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2250 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second tight chain comprises the amino acid sequence of SEQ ID NO: 2251. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2252 or a variant thereof in which the N-terminal glutamine is replaced w ith pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N- terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2258 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first tight chain comprises the amino acid sequence of SEQ ID NO: 2242. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed,Attorney Docket No. 078306 / 636740 and the second light chain compnses the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242. the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2250, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2251. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2252, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2258, the first light chain is at least 90%, at least 95%, at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244. and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245.

[0078] In some such antibodies, the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 asAttorney Docket No. 078306 / 636740 measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1 A with a KD of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0079] In another aspect, provided are bispecific or heterodimeric antibodies comprising: (a) a first monomer comprising a first heavy chain comprising a VL1-CH1 -hinge-CH2-CH3, wherein VL1 is a first variable light domain, CHl-hinge-CH2-CH3 is a first heavy chain constant domain, and CH2-CH3 is a first Fc domain; (b) a second monomer comprising a second heavy chain comprising a VH2-CHl-hinge-CH2-CH3, wherein VH2 is a second variable heavy domain, CHl-hinge-CH2-CH3 is a second heavy chain constant domain, and CH2-CH3 is a second Fc domain; (c) a first light chain comprising a VH1-CL, wherein VH1 is a first variable heavy domain, and CL is a first light chain constant domain; and (d) a second light chain comprising a VL2-CL, wherein VL2 is a second variable light domain, and CL is a second light chain constant domain, wherein the VH1 and VL1 together form a first antigen-binding domain (ABD), and the VH2 and the VL2 together form a second ABD, wherein the first ABD is a TL1 A-binding domain and the second ABD is an IL23-binding domain, or wherein the first ABD is an IL23-binding domain and the second ABD is a TL1 A- binding domain. For example, any of the above antibodies can be in this format.

[0080] In some such antibodies, the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants at positions 213 and 218 of the second heavy chain constant domain according to EU numbering and positions 122 and 123 of the second light chain constant domain according to Kabat numbering. In some such antibodies, the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants as depicted in Figure 4 orAttorney Docket No. 078306 / 636740Table 27. In some such antibodies, the second heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering, and the second light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering.

[0081] In some such antibodies, the first ABD is a TLlA-binding domain and the second ABD is an IL23 -binding domain.

[0082] In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674. 1200, 2241, 2253, and 2259, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and a variable light domain comprising a vlCDRl , a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within aAttorney Docket No. 078306 / 636740 variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising a vlCDRl. a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661. and 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 101, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 109, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 117, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence ofAttorney Docket No. 078306 / 636740SEQ ID NO: 121. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 125, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 133, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 141, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 149, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 157, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 161, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 169, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and aAttorney Docket No. 078306 / 636740 vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378. XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti- TLl A variable heavy domain and variable light domain in Tables 26 and 29-34. Optionally, the CDRs in any of the above antibodies are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

[0083] In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 compnsing the amino acid sequence of SEQ ID NO: 103, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 110, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 111, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 112, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 114, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 115, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 11 . In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 118, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 119. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 120. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 122, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 124. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 126, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 127, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 128, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 130. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 131, and a vlCDR3 comprising the amino acid sequence of the amino acid sequence of SEQ ID NO: 132. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising aAttorney Docket No. 078306 / 636740 vhCDRl comprising the amino acid sequence of SEQ ID NO: 134. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 135, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 136, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 138, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 139. and a vlCDR3 comprising the amino acid sequence of the amino acid sequence of SEQ ID NO: 140. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 142, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 143, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 144, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 146, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 147, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 148. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 150. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 151, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 152, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 154, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 155, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 156. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 118, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 158, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 120, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 122. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 160. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 162, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 163. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 164. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 166, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 167, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 168. In some such antibodies, the VH1 and VL1 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 170, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 171, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 172, and aAttorney Docket No. 078306 / 636740 variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 174, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 175, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 176.

[0084] In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 2241, 2253, and 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, atAttorney Docket No. 078306 / 636740 least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 101, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 109. and the VL1 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 117, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 125, and the VL1 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence SEQ ID NO: 133, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 141, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 149, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acidAttorney Docket No. 078306 / 636740 sequence of SEQ ID NO: 153. In some such antibodies, the VH1 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 157, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 161, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 169, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti- TL1A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavydomain and variable light domain in Tables 26 and 29-34.

[0085] In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 2241, 2253, and 2259, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674. and the VE1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some suchAttorney Docket No. 078306 / 636740 antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 101, and the VL1 comprises the amino acid sequence of SEQ ID NO: 105. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 109, and the VL1 comprises the amino acid sequence of SEQ ID NO: 113. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 117, and the VL1 comprises the amino acid sequence of SEQ ID NO: 121. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 125, and the VL1 comprises the amino acid sequence of SEQ ID NO: 129. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 133, and the VL1 comprises the amino acid sequence of SEQ ID NO: 137. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 141, and the VL1 comprises the amino acid sequence of SEQ ID NO: 145. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 149, and the VL1 comprises the amino acid sequence of SEQ ID NO: 153. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 157, and the VL1 comprises the amino acid sequence of SEQ ID NO: 159. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 161, and the VL1 comprises the amino acid sequence of SEQ ID NO: 165. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 169. and the VE1 comprises the amino acid sequence of SEQ ID NO: 173. In some such antibodies, the VH1 and the VL1 comprise any pair of anti- TL1 A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370. XENP53371, XENP53376, XENP53377, XENP53378, XENP53379. XENP53380. or XENP53414. In some such antibodies, the VH1 and the VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in Tables 26 and 29-34. In some such antibodies, the VH1 or VL1 can comprise variants of any of the above in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0086] In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domainAttorney Docket No. 078306 / 636740 comprising the amino acid sequence of any one of SEQ ID NOS: 179, 2233, and 2235. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO: 179. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 183. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-IL23 variable heavy domain and variable light domain in Tables 26 and 29-34. Optionally, the CDRs in any of the above antibodies are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

[0087] In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising theAttorney Docket No. 078306 / 636740 amino acid sequence of SEQ ID NO: 2239, a vhCDR2 comprising the ammo acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH2 and VL2 comprise a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 115, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 185.

[0088] In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 179, 2233. and 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical toAttorney Docket No. 078306 / 636740 the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 183. In some such antibodies, the VH2 and the VL2 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti- IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380. or XENP53414. In some such antibodies, the VH2 and the VL2 are at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in Tables 26 and 29-34.

[0089] In some such antibodies, the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 179, 2233, and 2235, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2233. and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 1967, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 1927-2132, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 183. In some such antibodies, the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412,Attorney Docket No. 078306 / 636740XENP53413, XENP53369, XENP53375, XENP53387. XENP53415. XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in Tables 26 and 29-34. In some such antibodies, the VH2 or VL2 can comprise variants of any of the above in which an N- terminal glutamine or glutamate is replaced with pyroglutamate.

[0090] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200. 2241, 2253, and 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 179, 2233. and 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 2241, 2253, and 2259, (ii) the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243, (iii) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 179, 2233, and 2235. and (iv) the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some suchAttorney Docket No. 078306 / 636740 antibodies, the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity in a TL1A luciferase reporter assay with an IC50 of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an IC50 of less than about 60 pM. less than about 59 pM. less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0091] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674 or 1200. (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:Attorney Docket No. 078306 / 636740184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674 or 1200, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179. and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a Ko of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C. optionally wherein the bispecific antibody specifically binds human TL 1 A with a KD of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity7in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about L IE- 10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity7in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity yvith an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0092] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained yvithin a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally yvherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises aAttorney Docket No. 078306 / 636740 vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182. and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0093] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, (ii) the VL1 comprises a vlCDRl , a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the ammo acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence SEQ ID NO: 1200, (ii) the VL1 comprises the amino acid sequence ofAttorney Docket No. 078306 / 636740SEQ ID NO: 1204. (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0094] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the bispecific antibody specifically binds human TL1A with a Ko of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C. optionally wherein the bispecific antibody specifically binds human TL 1 A with a KD of less than about 3E- 11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporterAttorney Docket No. 078306 / 636740 assay with an IC50 of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a Kn of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M. or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0095] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2237, orAttorney Docket No. 078306 / 636740 variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0096] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2253. (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0097] In some such antibodies, the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2Attorney Docket No. 078306 / 636740 comprises a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0098] In some such antibodies, the first Fc domain and the second Fc domain comprise a set of heterodimerization skew variants. In some such antibodies, the first Fc domain and the second Fc domain each comprise one or more ablation variants. In some such antibodies, the first monomer or the second monomer comprises one or more pl variants. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constantAttorney Docket No. 078306 / 636740 domain or the second heavy chain constant domain comprises amino acid substitutions E368D / K370S, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions L368D / K370S, and the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428E / N434S, and E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the first heavy chain constant domain comprises amino acid substitutions E233P / E234V / L235A / G236del / S267K. M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering, and the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering.

[0099] In some such antibodies, the first heavy chain constant domain is of isotype IgGl, and the second heavy chain constant domain is of isotype IgGl. In some such antibodies, the bispecific antibody is a chimeric or humanized bispecific antibody.

[0100] In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C- terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2265 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2269 or a variant thereof in which the N-terminalAttorney Docket No. 078306 / 636740 glutamine is replaced with pyroglutamate. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2265. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2269. In some such antibodies, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C -terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2267. In some such antibodies, the second heavy chain is at least 90%, at least 95%, at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267.

[0101] In some such antibodies, the first heavy chain, the first light chain, the second heavy chain, and the second light chain comprise any set of four chains from Table 31 or 32. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2265 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C- terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2267. In some such antibodies, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2269 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acidAttorney Docket No. 078306 / 636740 sequence of SEQ ID NO: 2267. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2265, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267. In some such antibodies, the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2269, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267.

[0102] In some such antibodies, the bispecific antibody specifically binds human TL1A with a Ko of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human TL1 A with a KD of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the bispecific antibody inhibits TL1A activity’ in a TL1A luciferase reporter assay with an ICso of less than about 4.5 nM. In some such antibodies, the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a Kn of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M. or less than about 5.7E-11 M. In some such antibodies, the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an ICso of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an ICso of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

[0103] In another aspect, provided is a bispecific antibody comprising: (a) a means for binding TL1A; and (b) a means for binding IL23. In another aspect, provided is aAttorney Docket No. 078306 / 636740 pharmaceutical composition compnsing: (a) the above bispecific antibody; and (b) a pharmaceutically acceptable carrier. In another aspect, provided is a pharmaceutical composition comprising: (a) a first composition comprising a means for binding TL1A; and (b) a second composition comprising a means for binding IL23. In another aspect, provided is a pharmaceutical composition comprising: (a) a means for binding TL1A; (b) a means for binding IL23; and (c) a pharmaceutically acceptable carrier.

[0104] In another aspect, provided are pharmaceutical compositions comprising any of the above bispecific antibodies and a pharmaceutically acceptable carrier. In another aspect, provided are kits comprising any of the above bispecific antibodies or pharmaceutical compositions. In another aspect, provided are vessels or delivery devices comprising any of the above bispecific antibodies or pharmaceutical compositions. In another aspect, provided are nucleic acid compositions comprising a nucleic acid or a set of nucleic acids encoding any of the above bispecific antibodies. In another aspect, provided are expression vector compositions comprising an expression vector or a set of expression vectors comprising the above nucleic acid composition. In another aspect, provided are host cells comprising the expression vector composition. In another aspect, provided are methods of making a bispecific antibody, comprising culturing the host cell under conditions wherein the bispecific antibody is expressed, and recovering the bispecific antibody.

[0105] In another aspect, provided are methods of inhibiting or reducing TL1 A- mediated activity and / or IL23-mediated activity in a subject in need thereof, comprising administering to the subject any of the above bispecific antibodies or pharmaceutical compositions. In another aspect, provided are any of the above bispecific antibodies or pharmaceutical compositions for use in inhibiting or reducing TLlA-mediated activity and / or IL23-mediated activity’ in a subject in need thereof. In another aspect, provided are uses of any of the above bispecific antibodies or pharmaceutical compositions for inhibiting or reducing TL1 A-mediated activity and / or IL23-mediated activity in a subject in need thereof. In another aspect, provided are uses of any of the above bispecific antibodies or pharmaceutical compositions in the manufacture of a medicament for inhibiting or reducing TLlA-mediated activity and / or IL23-mediated activity in a subject in need thereof.

[0106] In another aspect, provided are methods of treating a TL1 A-associated disease and / or IL23-associated disease in a subject in need thereof, comprising administering to the subject any of the above bispecific antibodies or pharmaceutical compositions. In another aspect, provided are any of the above bispecific antibodies or pharmaceutical compositionsAttorney Docket No. 078306 / 636740 for use in the treatment of a TL1 A-associated disease and / or 1L23 -associated disease in a subject in need thereof. In another aspect, provided are uses of any of the above bispecific antibodies or pharmaceutical compositions for the treatment of a TL1 A-associated disease and / or IL23-associated disease in a subject in need thereof. In another aspect, provided are uses of any of the above bispecific antibodies or pharmaceutical compositions in the manufacture of a medicament for the treatment of a TL1 A-associated disease and / or IL23- associated disease in a subject in need thereof. In some such methods, antibodies or compositions for use, or uses, the TL1 A-associated disease and / or IL23-associated disease is an inflammatory disease, an autoimmune disease, or a fibrotic disease, optionally wherein the TL1 A-associated disease and / or IL23-associated disease is an inflammatory bowel disease. In some such methods, antibodies or compositions for use, or uses, the subject is a human.

[0107] In another aspect, provided are antibodies comprising a TNF-like ligand 1 A (TL1A) antigen-binding domain. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241 , 2253, 2259, 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl. a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence ofAttorney Docket No. 078306 / 636740SEQ ID NO: 1674. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661 , and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379. XENP53380, or XENP53414. Optionally, the CDRs in any of the above antibodies are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

[0108] In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2Attorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO: 107. and a vlCDR3 compnsing the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the antibody comprises a variable heavy’ domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108.

[0109] In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO: 2241, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the variable light domain is at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259. and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the variable light domain is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the variable light domain is at least 90%. at least 95%, at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the variable light domain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to theAttorney Docket No. 078306 / 636740 amino acid sequence of SEQ ID NO: 2323, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain and the variable light domain are at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the variable heavy domain and the variable light domain are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in Table 29 or 33.

[0110] In some such antibodies, the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2241. 2253, 2259, 1674, and 1200, and the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2241, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2253, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2259, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1674. and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1200, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 1824-1923. In some such antibodies, the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661, and 2323, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1661, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, theAttorney Docket No. 078306 / 636740 variable heavy domain comprises the ammo acid sequence of SEQ ID NO: 2323. and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204. In some such antibodies, the variable heavy domain and the variable light domain comprise any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413. XENP53369, XENP53375, XENP53387, XENP53415. XENP53370. XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the variable heavy domain and the variable light domain comprise any pair of anti-TLl A variable heavy domain and variable light domain in Table 29 or 33. In some such antibodies, the variable heavy domain or the variable light domain can comprise variants of any of the above in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0111] In some such antibodies, (i) the variable heavy domain comprises a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259. 1674, and 1200, and (ii) the variable light domain comprises a vlCDRl , a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition. In some such antibodies, (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, (i) the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and (ii) the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, or variants thereof in which an N- terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the antibody specifically binds human TL1 A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the antibody specifically binds human TL1A with a KD of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E-11 M, or lessAttorney Docket No. 078306 / 636740 than about 2.7E-11 M. In some such antibodies, the antibody inhibits TL1A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM.

[0112] In some such antibodies, (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241. and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition. In some such antibodies, (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2241 , and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate. In some such antibodies, the antibody specifically binds human TLIA with a Ko of less than about 6.5E-11 M, less than about 6.4 E-l l M, or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E- 11 M, or less than about 2.7E-11 M. In some such antibodies, the antibody inhibits TL1A activity in a TE1 A luciferase reporter assay with an IC50 of less than about 4.5 nM.

[0113] In some such antibodies, (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, aAttorney Docket No. 078306 / 636740 vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2253, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0114] In some such antibodies, (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition. In some such antibodies, (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104. and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2259, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0115] In some such antibodies, (i) the variable heavy domain comprises a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674. and (ii) the variable light domain comprises a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition. In some such antibodies, (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1674, and (ii) the variable lightAttorney Docket No. 078306 / 636740 domain comprises the amino acid sequence of SEQ ID NO: 1204, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0116] In some such antibodies, (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200. and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition. In some such antibodies, (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108. In some such antibodies, (i) the variable heavy domain comprises the amino acid sequence SEQ ID NO: 1200, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

[0117] In some such antibodies, the antibody is a chimeric or humanized antibody. In some such antibodies, the antibody is an antigen-binding fragment of an intact antibody.

[0118] In some such antibodies, the antibody comprises a heavy chain constant domain and a light chain constant domain. In some such antibodies, the heavy chain constant domain is of isotype IgGl.

[0119] In some such antibodies, the heavy chain constant domain comprise a set of heterodimerization skew variants. In some such antibodies, the heavy chain constant domain each comprise one or more ablation variants. In some such antibodies, the heavy chain constant domain comprises one or more pl variants. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K. wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions L368D / K370S, whereinAttorney Docket No. 078306 / 636740 numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S. and E357Q / S364K, wherein numbering is according to EU numbering. In some such antibodies, the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K, wherein numbering is according to Kabat numbering. In some such antibodies, the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E, wherein numbering is according to Kabat numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitution A141F and the light chain constant domain comprises amino acid substitution F118A, wherein numbering is according to EU numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions K213E / K218D and the light chain constant domain comprises amino acid substitutions D 122K / EI 23K. wherein numbering is according to EU numbering. In some such antibodies, the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering. In some such antibodies, the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitution A141F according to EU numbering and the light chain constant domain comprises amino acid substitution F118A according to Kabat numbering. In some such antibodies, the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises ammo acid substitution Q38K according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K,Attorney Docket No. 078306 / 636740M428L / N434S, L368D / K370S, N208D / Q295E / N384D / Q418E / N421D, and K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering. In some such antibodies, the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, E357Q / S364K, and A141F according to EU numbering and the light chain constant domain comprises amino acid substitution F118A according to Kabat numbering. In some such antibodies, the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, E357Q / S364K, and K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering.

[0120] In some such antibodies, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2252 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C- terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2258 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2265 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate. In some such antibodies, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2269 or aAttorney Docket No. 078306 / 636740 variant thereof in which the N -terminal glutamine is replaced with pyroglutamate. In some such antibodies, the antibody comprises a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, and a light chain at least 90%, at least 95%, at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the antibody comprises a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2252. and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the antibody comprises a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2258, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242. In some such antibodies, the antibody comprises a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2265. In some such antibodies, the antibody comprises a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2269.

[0121] In some such antibodies, the antibody specifically binds human TL1 A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M. or less than about 6.3E-11 as measured by surface plasmon resonance or Biacore at 25°C, optionally wherein the antibody specifically binds human TL1 A with a KD of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M. In some such antibodies, the antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM.

[0122] In some such antibodies, wherein the antibody is a bispecific antibody or multispecific antibody. In some such antibodies, the bispecific antibody or multispecific antibody further comprises an interleukin-23 (IL23) antigen-binding domain. In some such antibodies, the bispecific antibody or multispecific antibody further comprises a means for binding IL23.Attorney Docket No. 078306 / 636740

[0123] In another aspect, provided are pharmaceutical compositions comprising any of the above antibodies and a pharmaceutically acceptable carrier. Some such pharmaceutical compositions further comprise an antibody comprising an IL23 antigen-binding domain. In another aspect, provided are kits comprising any of the above antibodies or pharmaceutical compositions. In another aspect, provided is a vessel or delivery device comprising any of the above antibodies or pharmaceutical compositions. In another aspect, provided is a nucleic acid composition comprising a nucleic acid or a set of nucleic acids encoding any of the above antibodies. In another aspect, provided is an expression vector composition an expression vector or a set of expression vectors comprising the nucleic acid composition. In another aspect, provided is a host cell comprising the expression vector composition. In another aspect, provided is a method of making an anti-TLl A antibody, comprising culturing the host cell under conditions wherein anti-TLl A antibody is expressed, and recovering the anti-TLl A antibody.

[0124] In another aspect, provided is a method of inhibiting or reducing TL1A- mediated activity in a subject in need thereof, comprising administering to the subject any of the above antibodies or pharmaceutical compositions. In another aspect, provided are any of the above antibodies or pharmaceutical compositions for use in inhibiting or reducing TL1A- mediated activity in a subject in need thereof. In another aspect, provided is use of any of the above antibodies or pharmaceutical compositions for inhibiting or reducing TLlA-mediated activity in a subject in need thereof. In another aspect, provided is use of any of the above antibodies or pharmaceutical compositions in the manufacture of a medicament for inhibiting or reducing TL1 A-mediated activity in a subject in need thereof.

[0125] In another aspect, provided is a method of treating a TL1 A-associated disease in a subject in need thereof, comprising administering to the subject any of the above antibodies or pharmaceutical compositions. In another aspect, provided are any of the above antibodies or pharmaceutical compositions for use in the treatment of a TL1 A-associated disease in a subject in need thereof. In another aspect, provided is use of any of the above antibodies or pharmaceutical compositions for the treatment of a TL1 A-associated disease in a subject in need thereof. In another aspect, provided is use of any of the above antibodies or pharmaceutical compositions in the manufacture of a medicament for the treatment of a TL1 A-associated disease in a subject in need thereof. In some such methods, antibodies or pharmaceutical compositions for use, or uses, the TL1 A-associated disease is an inflammatory disease, an autoimmune disease, or a fibrotic disease, optionally wherein theAttorney Docket No. 078306 / 636740TLlA-associated disease is an inflammatory bowel disease. In some such methods, antibodies or pharmaceutical compositions for use, or uses, the subject is a human. In some such methods, antibodies or pharmaceutical compositions for use, or uses, the antibody comprising the TL1 A-antigen binding domain is used in combination with an antibody comprising an IL23 antigen-binding domain. In some such methods, antibodies or pharmaceutical compositions for use, or uses, the antibody comprising the IL23 antigenbinding domain and the antibody comprising the TL1 A antigen-binding domain are administered simultaneously. In some such methods, antibodies or pharmaceutical compositions for use, or uses, the antibody comprising the IL23 antigen-binding domain and the antibody comprising the TL1 A antigen-binding domain are administered sequentially in any order.

[0126] In another aspect, provided are antibodies comprising an interleukin-23 (IL23) antigen-binding domain comprising a variable heavy domain and a variable light domain. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy7domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the antibody comprises a variable heavy7domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and aAttorney Docket No. 078306 / 636740 vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the antibody comprises a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379. XENP53380, or XENP53414. Optionally, the CDRs in any of the above antibodies are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

[0127] In some such antibodies, the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies, the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250. In some such antibodies.Attorney Docket No. 078306 / 636740 the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.

[0128] In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2233. 2235, and 179. and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248. In some such antibodies, the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ IDAttomey Docket No. 078306 / 636740NOS: 1927-2132, and the variable light domain is at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2133-2232. In some such antibodies, the variable heavy domain and the variable light domain are at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414. In some such antibodies, the variable heavy domain and the variable light domain are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in Table 29 or 33.

[0129] In some such antibodies, the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2233. 2235, and 179. and the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248. In some such antibodies, the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2233, and the variable light domain comprises the amino acid sequence of SEQ ID...

Claims

Attorney Docket No. 078306 / 636740WHAT IS CLAIMED IS:

1. A bispecific antibody comprising:(a) a TL1 A-binding domain comprising a first variable heavy domain (VH1) and a first variable light domain (VL1); and(b) an IL23-binding domain comprising a second variable heavy domain (VH2) and a second variable light domain (VL2).

2. The bispecific antibody of claim 1, wherein:(a) the VH1 and VL1 are selected from:(1) (i) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Table 44, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(ii) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Tables 7-10, 22, 23, 26, 29-34, and 48, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; and(iii) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of 1824-1923, optionally wherein the CDRs are as defined by the Kabat. Chothia. Kabat + Chothia. AbM, contact, or IMGT definition;(2) (i) any pair of anti-TLl A variable heavy domain and variable light domain in Table 44; and(ii) any pair of anti-TL 1 A variable heavy domain and variable light domain in Tables 7-10, 22, 23, 26, 29-34, and 48; and(iii) a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising the amino acid sequence of any one of 1824-1923,Attorney Docket No. 078306 / 636740 or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; and / or(b) the VH2 and VL2 are selected from:(1) (i) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Table 44, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(ii) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Tables 11, 24-26, 29-34, and 49, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(iii) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of 1927-2132, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of 2133-2232, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(2) (i) any pair of anti-IL23 variable heavy domain and variable light domain in Table 44; and(ii) any pair of anti-IL23 variable heavy domain and variable light domain in Tables 11. 24-26. 29-34, and 49; and(iii) a variable heavy domain comprising the amino acid sequence of any one of 1927-2132, and a variable light domain comprising the amino acid sequence of any one of 2133-2232, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

3. The bispecific antibody of claim 1, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence ofAttorney Docket No. 078306 / 636740 any one of SEQ ID NOS: 2241, 2253. 2259. 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(d) a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(f) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(g) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;Attorney Docket No. 078306 / 636740(h) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204; and(i) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387. XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

4. The bispecific antibody' of claim 1, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(b) a vanable heavy' domain comprising a vhCDRl comprising the ammo acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; and(e) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108.

5. The bispecific antibody of any one of claims 1-4, wherein:(a) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(c) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(d) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;Attorney Docket No. 078306 / 636740(e) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(I) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(g) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204; or(i) the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

6. The bispecific antibody of claim 1. wherein:(a) the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(c) the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(d) the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;Attorney Docket No. 078306 / 636740(e) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(I) the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(g) the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 comprises the amino acid sequence of SEQ ID NO: 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204; or(i) the VH1 and the VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

7. The bispecific antibody of any one of claims 1-6, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248;(b) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237;Attorney Docket No. 078306 / 636740(d) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248;(e) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231;(f) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248; and(g) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition.

8. The bispecific antibody of any one of claims 1-6, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;Attorney Docket No. 078306 / 636740(b) a vanable heavy domain comprising a vhCDRl comprising the ammo acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250:(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; and(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181 , and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.

9. The bispecific antibody of any one of claims 1-8, wherein:(a) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS:2233. 2235, and 179. and the VL2 is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS:2234, 2237, and 1248;(b) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234;(c) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237;Attorney Docket No. 078306 / 636740(d) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248;(e) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231;(I) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

10. The bispecific antibody of any one of claims 1-6, wherein:(a) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237. and 1248;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234;(c) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237;(d) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248;(e) the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231 ;(I) the VH2 comprises the amino acid sequence of SEQ ID NO: 1967, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248; orAttorney Docket No. 078306 / 636740(g) the VH2 and the VL2 comprise any pair of anti-lL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

11. The bispecific antibody of any one of claims 1-10, wherein:(a) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, (ri) the VL1 compnses a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248, optionally wherein the CDRs are as defined by the Kabat. Chothia, Kabat + Chothia. AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, (ii) the VL1 comprises the ammo acidAttorney Docket No. 078306 / 636740 sequence of any one of SEQ ID NOS: 2243 and 1204. (iii) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(b) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(c) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(d) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; orAttorney Docket No. 078306 / 636740(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233. and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(e) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233. and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequenceAttorney Docket No. 078306 / 636740 of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO:2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(I) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2Attorney Docket No. 078306 / 636740 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; or(g) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201 , a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence SEQ ID NO: 1200, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

12. The bispecific antibody of any one of claims 1-11, wherein the bispecific antibody comprises (i) a first heavy chain comprising the VH1 and a first heavyAttorney Docket No. 078306 / 636740 chain constant domain, (ii) a first light chain comprising the VL1 and a first light chain constant domain, (iii) a second heavy chain comprising the VH2 and a second heavy chain constant domain, and (iv) a second light chain comprising the VL2 and a second light chain constant domain.

13. The bispecific antibody of claim 12, wherein:(a) the first heavy chain constant domain and the second heavy chain constant domain comprise a set of heterodimerization skew variants; and / or(b) the first heavy chain constant domain and the second heavy chain constant domain each comprise one or more ablation variants; and / or(c) the first heavy chain constant domain or the second heavy chain constant domain comprises one or more pl variants.

14. The bispecific antibody of claim 12 or 13, wherein:(a) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering;(b) the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering;(c) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering;(d) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions L368D / K370S, wherein numbering is according to EU numbering;(e) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;Attorney Docket No. 078306 / 636740(f) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(g) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;(h) the first heavy chain constant domain comprises amino acid substitutions L368D / K370S. and the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;(i) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering; or(j) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering, and the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering.

15. The bispecific antibody of any one of claims 12-14, wherein the first heavy chain constant domain is of isotype IgGl, and the second heavy chain constant domain is of isotype IgGl.

16. The bispecific antibody of any one of claims 1-15, wherein the bispecific antibody is a chimeric or humanized bispecific antibody.

17. The bispecific antibody of any one of claims 1-16, wherein:(a) the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M. less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance at 25°C, optionally wherein the bispecific antibodyAttorney Docket No. 078306 / 636740 specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M; and / or(b) the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM; and / or(c) the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M; and / or(d) the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

18. A bispecific antibody comprising:(a) a first monomer comprising a first heavy chain comprising a VH1- CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain, CHl-hinge-CH2-CH3 is a first heavy chain constant domain, and CE12-CH3 is a first Fc domain;(b) a second monomer comprising a second heavy chain comprising a VH2-CHl-hinge-CH2-CH3, wherein VH2 is a second variable domain, CHl-hinge-CH2- CH3 is a second heavy chain constant domain, and CH2-CH3 is a second Fc domain;(c) a first light chain comprising a VL 1 -CL, wherein VL l is a first variable light domain, and CL is a first light chain constant domain; and(d) a second light chain comprising a VL2-CL, wherein VL2 is a second variable light domain, and CL is a second light chain constant domain, wherein the VH1 and VL1 together form a first antigen-binding domain (ABD), and the VH2 and the VL2 together form a second ABD, wherein the first ABD is a TL1 A-binding domain and the second ABD is an IL23-binding domain, or wherein the first ABD is an IL23-binding domain and the second ABD is a TLlA-binding domain, and wherein:(i) the first heavy chain constant domain and the first light chain constant domain comprise a set of electrostatic steering variants at positions 213 and 218 of the firstAttorney Docket No. 078306 / 636740 heavy chain constant domain according to EU numbering and positions 122 and 123 of the first light chain constant domain according to Kabat numbering, or a set of steric skew variants at position 141 of the first heavy chain constant domain according to EU numbering and position 118 of the first light chain constant domain according to Kabat numbering, at position 141 of the first heavy chain constant domain according to EU numbering and position 116 of the first light chain constant domain according to Kabat numbering, or at position 147 of the first heavy chain constant domain according to EU numbering and position 131 of the first light chain constant domain according to Kabat numbering; and / or(ii) the VH1 and the VL1 comprise a set of electrostatic steering variants at position 39 of VH1 and position 38 ofVLl according to Kabat numbering; and / or(iii) the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants at positions 213 and 218 of the second heavy chain constant domain according to EU numbering and positions 122 and 123 of the second light chain constant domain according to Kabat numbering, or a set of steric skew variants at position 141 of the second heavy chain constant domain according to EU numbering and position 118 of the second light chain constant domain according to Kabat numbering, at position 141 of the second heavy chain constant domain according to EU numbering and position 116 of the second light chain constant domain according to Kabat numbering, or at position 147 of the second heavy chain constant domain according to EU numbering and position 131 of the second light chain constant domain according to Kabat numbering; and / or(iv) the VH2 and the VL2 comprise a set of electrostatic steering variants at position 39 of VH2 and position 38 of VL2 according to Kabat numbering.

19. The bispecific antibody of claim 18, wherein:(a) the first heavy chain constant domain and the first light chain constant domain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27 or a set of steric skew variants as depicted in Figure 5 or Table 28;(b) the VH1 and the VL1 comprise a set of electrostatic steering variants as depicted in Figure 6 or Table 18 or 19;Attorney Docket No. 078306 / 636740(c) the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27 or a set of steric skew variants as depicted in Figure 5 or Table 28; and / or(d) the VH2 and the VL2 comprise a set of electrostatic steering variants as depicted in Figure 6 or Table 18 or 19.

20. The bispecific antibody of claim 18 or 19, wherein:(a) the VH1 comprises amino acid substitution Q39E and the VL1 comprises amino acid substitution Q38K according to Kabat numbering;(b) the VH2 comprises amino acid substitution Q39K and the VL2 comprises amino acid substitution Q38E according to Kabat numbering; or(c) the VH1 comprises amino acid substitution Q39E, the VL1 comprises amino acid substitution Q38K. the VH2 comprises amino acid substitution Q39K, and the VL2 comprises amino acid substitution Q38E according to Kabat numbering.

21. The bispecific antibody of any one of claims 18-20, wherein the first heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering, and the first light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering.

22. The bispecific antibody of any one of claims 18-21, wherein the second heavy chain constant domain comprises amino acid substitution A141F according to EU numbering, and the second light chain constant domain comprises amino acid substitution F 118A according to Kabat numbering.

23. The bispecific antibody of any one of claims 18-22, wherein:(a) the VH1 comprises amino acid substitution Q39E, the VL1 comprises amino acid substitution Q38K, the VH2 comprises amino acid substitution Q39K, and the VL2 comprises amino acid substitution Q38E according to Kabat numbering;(b) the first heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering, and the first light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering; andAttorney Docket No. 078306 / 636740(c) the second heavy chain constant domain comprises amino acid substitution A141F according to EU numbering, and the second light chain constant domain comprises amino acid substitution F118A according to Kabat numbering.

24. The bispecific antibody of any one of claims 18-23, wherein the first ABD is a TLlA-binding domain and the second ABD is an IL23-binding domain.

25. The bispecific antibody of claim 24, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(d) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and a variable light domain comprising a vlCDRl, a vlCDR2, and aAttorney Docket No. 078306 / 636740 vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(f) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(g) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(h) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204; and(i) a variable heavy’ domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378. XENP53379, XENP53380, or XENP53414. optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

26. The bispecific antibody of claim 24, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the aminoAttorney Docket No. 078306 / 636740 acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(b) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; and(e) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108.

27. The bispecific antibody of any one of claims 24-26, wherein:(a) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 is at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;Attorney Docket No. 078306 / 636740(b) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(c) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(d) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(e) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(f) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(g) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204; or(i) the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.Attorney Docket No. 078306 / 63674028. The bispecific antibody of claim 24, wherein:(a) the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674. and 1200, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(c) the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(d) the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(e) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(f) the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(g) the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 comprises the amino acid sequence of SEQ ID NO: 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204; or(i) the VH1 and the VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

29. The bispecific antibody of any one of claims 24-28, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248;Attorney Docket No. 078306 / 636740(b) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234;(c) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237;(d) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231;(f) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248; and(g) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378. XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.Attorney Docket No. 078306 / 63674030. The bispecific antibody of any one of claims 24-28, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;(b) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250:(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; and(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.

31. The bispecific antibody of any one of claims 24-30, wherein:(a) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, atAttorney Docket No. 078306 / 636740 least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248;(b) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234;(c) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237;(d) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248;(e) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231;(I) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 are at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

32. The bispecific antibody of any one of claims 24-28, wherein:(a) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248;Attorney Docket No. 078306 / 636740(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234;(c) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237;(d) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248;(e) the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231 ;(I) the VH2 comprises the amino acid sequence of SEQ ID NO: 1967, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

33. The bispecific antibody of any one of claims 24-32, wherein:(a) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, and 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233 or 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234 or 2237, optionally wherein the CDRs are as defined by the Kabat. Chothia, Kabat + Chothia. AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and aAttorney Docket No. 078306 / 636740 vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (lii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of any one ofSEQ ID NOS: 2241, 2253. and 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233 or 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234 or 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(b) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; orAttorney Docket No. 078306 / 636740(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO:2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(c) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237, optionally wherein the CDRs are as defined by the Kabat, Chothia, Rabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;Attorney Docket No. 078306 / 636740(d) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233. and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; or(e) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domainAttorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

34. The bispecific antibody of any one of claims 18-33, wherein:(a) the first Fc domain and the second Fc domain comprise a set of heterodimerization skew variants; and / or(b) the first Fc domain and the second Fc domain each comprise one or more ablation variants; and / or(c) the first monomer or the second monomer comprises one or more pl variants.

35. The bispecific antibody of any one of claims 18-34, wherein:(a) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering;Attorney Docket No. 078306 / 636740(b) the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering;(c) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering;(d) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions L368D / K370S, wherein numbering is according to EU numbering;(e) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(f) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(g) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;(h) the first heavy chain constant domain comprises amino acid substitutions L368D / K370S. and the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;(i) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering; or(j) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering, andAttorney Docket No. 078306 / 636740 the second heavy chain constant domain compnses amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering.

36. The bispecific antibody of any one of claims 18-35, wherein the first heavy chain constant domain is of isotype IgGl, and the second heavy chain constant domain is of isotype IgGl.

37. The bispecific antibody of any one of claims 18-36, wherein the bispecific antibody is a chimeric or humanized bispecific antibody.

38. The bispecific antibody of any one of claims 18-37, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2242;(b) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2252 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2242;(c) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2258 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2242;(d) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242;(e) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2252, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242; orAttorney Docket No. 078306 / 636740(f) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2258, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242.

39. The bispecific antibody of any one of claims 18-37, wherein:(a) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245;(b) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2250 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2251;(c) the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245; or(d) the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2250, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2251.

40. The bispecific antibody of any one of claims 18-37, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ IDNO: 1132 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1134, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1133 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1135;Attorney Docket No. 078306 / 636740(b) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1136 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1138. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1137 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1139;(c) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1084 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1086, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1085 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1087;(d) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1108 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1110, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1109 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1111;(e) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1088 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1090, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1089 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1091;Attorney Docket No. 078306 / 636740(f) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1092 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1094, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1093 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1095;(g) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1112 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1114, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1113 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1115;(h) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1116 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1118, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1117 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1119;(i) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1120 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1122, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1121 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1123;Attorney Docket No. 078306 / 636740(j) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1124 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1126. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1125 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1127;(k) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1128 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 1130, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1129 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1131;(l) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 1140, the first light chain comprises the amino acid sequence of SEQ ID NO: 1142, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 1141, and the second light chain comprises the amino acid sequence of SEQ ID NO: 1143;(m) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1132, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1134, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1133, and the second light chain is at least 90%, at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1135;(n) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1136, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1138, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identicalAttorney Docket No. 078306 / 636740 to the amino acid sequence of SEQ ID NO: 1137. and the second light chain is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1139;(o) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1084, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1086, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1085, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1087;(p) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1108, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1110, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1109, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1111;(q) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1088, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1090. the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1089, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1091;(r) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1092, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1094, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1093, and the second light chain is at least 90%,Attorney Docket No. 078306 / 636740 at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1095;(s) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1112, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1114, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1113, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1115;(t) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1116, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1118. the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1117, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1119;(u) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1120, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1122, the second heavy chain is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1121, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1123;(v) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1124, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1126, the second heavy chain is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1125, and the second light chain is at least 90%,Attorney Docket No. 078306 / 636740 at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1127;(w) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1128, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 1130, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1129, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1131;(x) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1140, the first light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1142. the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1141, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1143; or(y) the first heavy chain, the first light chain, the second heavy chain, and the second light chain comprise any set of four chains from Table 29.

41. The bispecific antibody of any one of claims 18-37, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245;(b) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed,Attorney Docket No. 078306 / 636740 the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2250 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2251;(c) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2252 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245;(d) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2258 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2242, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2245;(e) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245;(I) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chainAttorney Docket No. 078306 / 636740 is at least 90%. at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2250, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2251;(g) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2252, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chain is at least 90%. at least 95%. at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245; or(h) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2258, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245.

42. The bispecific antibody of any one of claims 18-41, wherein:(a) the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance at 25°C, optionally wherein the bispecific antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E- 11 M, or less than about 2.7E- 11 M; and / or(b) the bi specific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an ICso of less than about 4.5 nM; and / or(c) the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a Kn of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M; and / orAttorney Docket No. 078306 / 636740(d) the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity7with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM. or less than about 56 pM.

43. A bispecific antibody comprising:(a) a first monomer comprising a first heavy chain comprising a VL1- CHl-hinge-CH2-CH3. wherein VL1 is a first variable light domain, CHl-hinge-CH2-CH3 is a first heavy chain constant domain, and CH2-CH3 is a first Fc domain;(b) a second monomer comprising a second heavy chain comprising a VH2-CHl-hinge-CH2-CH3, wherein VH2 is a second variable heavy domain, CHl-hinge- CH2-CH3 is a second heavy chain constant domain, and CH2-CH3 is a second Fc domain;(c) a first light chain comprising a VH1-CL. wherein VH1 is a first variable heavy domain, and CL is a first light chain constant domain; and(d) a second light chain comprising a VL2-CL, wherein VL2 is a second variable light domain, and CL is a second light chain constant domain, wherein the VH1 and VL1 together form a first antigen-binding domain (ABD), and the VH2 and the VL2 together form a second ABD, wherein the first ABD is a TL1 A-binding domain and the second ABD is an IL23-binding domain, or wherein the first ABD is an IL23-binding domain and the second ABD is a TL1 A-binding domain.

44. The bispecific antibody of claim 43, wherein the second heavy chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants at positions 213 and 218 of the second heavy chain constant domain according to EU numbering and positions 122 and 123 of the second light chain constant domain according to Kabat numbering.

45. The bispecific antibody of claim 43 or 44, wherein the second heavy' chain constant domain and the second light chain constant domain comprise a set of electrostatic steering variants as depicted in Figure 4 or Table 27.Attorney Docket No. 078306 / 63674046. The bispecific antibody of any one of claims 43-45, wherein the second heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering, and the second light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering.

47. The bispecific antibody of any one of claims 43-46, wherein the first ABD is a TLlA-binding domain and the second ABD is an IL23 -binding domain.

48. The bispecific antibody of claim 47, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 2241. 2253, and 2259, and a variable light domain comprising a vlCDRl. a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243;(b) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(d) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and aAttorney Docket No. 078306 / 636740 vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(f) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(g) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(h) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204; and(i) a variable heavy’ domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378. XENP53379, XENP53380, or XENP53414. optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

49. The bispecific antibody of claim 47, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the aminoAttorney Docket No. 078306 / 636740 acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(b) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; and(e) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108.

50. The bispecific antibody of any one of claims 47-49, wherein:(a) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 2241, 2253, and 2259, and the VL1 is at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243;Attorney Docket No. 078306 / 636740(b) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(c) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(d) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(e) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(f) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(g) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204; or(i) the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.Attorney Docket No. 078306 / 63674051. The bispecific antibody of claim 49, wherein:(a) the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 2241, 2253. and 2259, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 1204 and 2243;(b) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(c) the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(d) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(e) the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(f) the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(g) the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 comprises the amino acid sequence of SEQ ID NO: 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204; or(i) the VH1 and the VL1 comprise any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

52. The bispecific antibody of any one of claims 47-51, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS:

179. 2233, and 2235, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237;Attorney Docket No. 078306 / 636740(b) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248;(c) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234;(d) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231;(f) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248; and(g) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2. and a vlCDR3 contained within any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378. XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.Attorney Docket No. 078306 / 63674053. The bispecific antibody of any one of claims 47-51, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;(b) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250:(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; and(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.

54. The bispecific antibody of any one of claims 47-53, wherein:(a) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 179, 2233, and 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, atAttorney Docket No. 078306 / 636740 least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237;(b) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248;(c) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234;(d) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237;(e) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231;(I) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 are at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

55. The bispecific antibody of any one of claims 47-51, wherein:(a) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 179, 2233. and 2235, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 1248, 2234, and 2237;Attorney Docket No. 078306 / 636740(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248;(c) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234;(d) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237;(e) the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231 ;(I) the VH2 comprises the amino acid sequence of SEQ ID NO: 1967, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 comprise any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

56. The bispecific antibody of any one of claims 47-55, wherein:(a) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674 or 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavydomain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRlAttorney Docket No. 078306 / 636740 comprising the amino acid sequence of SEQ ID NO:

180. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO:1674 or 1200, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(b) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2Attorney Docket No. 078306 / 636740 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; or(c) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201 , a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence SEQ ID NO: 1200, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

57. The bispecific antibody of any one of claims 43-56, wherein:Attorney Docket No. 078306 / 636740(a) the first Fc domain and the second Fc domain comprise a set of heterodimerization skew variants; and / or(b) the first Fc domain and the second Fc domain each comprise one or more ablation variants; and / or(c) the first monomer or the second monomer comprises one or more pl variants.

58. The bispecific antibody of any one of claims 43-57, wherein:(a) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering;(b) the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering;(c) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering;(d) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions L368D / K370S, wherein numbering is according to EU numbering;(e) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(f) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(g) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;Attorney Docket No. 078306 / 636740(h) the first heavy chain constant domain comprises amino acid substitutions L368D / K370S, and the second heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;(i) the first heavy chain constant domain or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K. M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering; or j) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering, and the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering.

59. The bispecific antibody of any one of claims 43-58, wherein the first heavy chain constant domain is of isotype IgGl, and the second heavy chain constant domain is of isotype IgGl.

60. The bispecific antibody of any one of claims 43-59, wherein the bispecific antibody is a chimeric or humanized bispecific antibody.

61. The bispecific antibody of any one of claims 43-60, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2265 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate;(b) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and the first light chain comprises the amino acid sequence of SEQ ID NO: 2269 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate;Attorney Docket No. 078306 / 636740(c) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2265; or(d) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2269.

62. The bispecific antibody of any one of claims 43-60, wherein:(a) the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2267; or(b) the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266, and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267.

63. The bispecific antibody of any one of claims 43-60, wherein the first heavy chain, the first light chain, the second heavy chain, and the second light chain comprise any set of four chains from Table 32.

64. The bispecific antibody of any one of claims 43-60, wherein:(a) the first heavy chain comprises the amino acid sequence of SEQ IDNO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2265 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C- terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2267;Attorney Docket No. 078306 / 636740(b) the first heavy chain comprises the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, the first light chain comprises the amino acid sequence of SEQ ID NO: 2269 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C- terminal lysine or the C-terminal lysine and glycine are removed, and the second light chain comprises the amino acid sequence of SEQ ID NO: 2267;(c) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2265, the second heavy chain is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266. and the second light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267; or(d) the first heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, the first light chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2269, the second heavy chain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266, and the second light chain is at least 90%, at least 95%. at least 96%. at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267.

65. The bispecific antibody of any one of claims 43-64, wherein:(a) the bispecific antibody specifically binds human TL1A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance at 25°C, optionally wherein the bispecific antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E- 11 M, less than about 2.8E-11 M, or less than about 2.7E-l l M; and / or(b) the bispecific antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM; and / orAttorney Docket No. 078306 / 636740(c) the bispecific antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance at 25°C, optionally wherein the bispecific antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M. less than about 5.8E-11 M, or less than about 5.7E-11 M; and / or(d) the bispecific antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the bispecific antibody inhibits IL23 activity with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

66. A bispecific antibody comprising:(a) a means for binding TL1 A; and(b) a means for binding IL23.

67. A pharmaceutical composition comprising:(a) the bispecific antibody of claim 1; and(b) a pharmaceutically acceptable carrier.

68. A pharmaceutical composition comprising:(a) a first composition comprising a means for binding TL1 A; and(b) a second composition comprising a means for binding IL23.

69. A pharmaceutical composition comprising:(a) a means for binding TL 1 A;(b) a means for binding IL23; and(c) a pharmaceutically acceptable carrier.

70. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1-66 and a pharmaceutically acceptable carrier.

71. A kit comprising the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70.Attorney Docket No. 078306 / 63674072. A vessel or delivery device comprising the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70.

73. A nucleic acid composition comprising a nucleic acid or a set of nucleic acids encoding the bispecific antibody of any one of claims 1-66.

74. An expression vector composition comprising an expression vector or a set of expression vectors comprising the nucleic acid composition of claim 73.

75. A host cell comprising the expression vector composition of claim 74.

76. A method of making a bispecific antibody, comprising culturing the host cell of claim 75 under conditions wherein the bispecific antibody is expressed, and recovering the bispecific antibody.

77. A method of inhibiting or reducing TL1 A-mediated activity and / or IL23-mediated activity in a subject in need thereof, comprising administering to the subject the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70.

78. The bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70 for use in inhibiting or reducing TLlA-mediated activity and / or lL23-mediated activity in a subject in need thereof.

79. Use of the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70 for inhibiting or reducing TL1A- mediated activity and / or IL23-mediated activity in a subject in need thereof.

80. Use of the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70in the manufacture of a medicament for inhibiting or reducing TL1 A-mediated activity and / or IL23 -mediated activity in a subject in need thereof.Attorney Docket No. 078306 / 63674081. A method of treating a TL1 A-associated disease and / or 1L23- associated disease in a subject in need thereof, comprising administering to the subject the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70.

82. The bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70 for use in the treatment of a TL1 A- associated disease and / or IL23-associated disease in a subject in need thereof.

83. Use of the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70 for the treatment of a TLlA- associated disease and / or IL23-associated disease in a subject in need thereof.

84. Use of the bispecific antibody of any one of claims 1-66 or the pharmaceutical composition of any one of claims 67-70 in the manufacture of a medicament for the treatment of a TLlA-associated disease and / or IL23 -associated disease in a subject in need thereof.

85. The method of claim 81, the bispecific antibody or the pharmaceutical composition for use of claim 82, or the use of claim 83 or 84, wherein the TLlA-associated disease and / or IL23-associated disease is an inflammatory disease, an autoimmune disease, or a fibrotic disease, optionally wherein the TLlA-associated disease and / or IL23-associated disease is an inflammatory bowel disease.

86. The method of any one of claims 77, 81, and 85, the bispecific antibody or the pharmaceutical composition for use of any one of claims 78, 82, and 85, or the use of any one of claims 79, 80, and 83-85, wherein the subject is a human.

87. An antibody comprising a TNF-like ligand 1 A (TL1A) antigen-binding domain comprising a variable heavy domain and a variable light domain selected from the following sets of variable heavy domains and variable light domains:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence ofAttorney Docket No. 078306 / 636740 any one of SEQ ID NOS: 2241, 2253. 2259. 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(d) a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(f) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(g) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1674, 1200, 1661. and 2323, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;Attorney Docket No. 078306 / 636740(h) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(i) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204; and(j) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387. XENP53415. XENP53370, XENP53371 , XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition.

88. The antibody of claim 87, wherein:(a) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(b) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;Attorney Docket No. 078306 / 636740(c) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(d) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; or(e) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108.

89. The antibody of claim 87 or 88, wherein:(a) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241. 2253. 2259, 1674, and 1200. and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(c) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;Attorney Docket No. 078306 / 636740(d) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(e) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(I) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(g) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(h) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204; or(i) the variable heavy domain and the variable light domain are at least 90%. at least 95%. at least 96%. at least 97%. at least 98%, or at least 99% identical to any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379. XENP53380, or XENP53414.

90. The antibody of any one of claims 87-89, wherein:(a) the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674. and 1200, and the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;Attorney Docket No. 078306 / 636740(b) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2241, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243;(c) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2253, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243;(d) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2259, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243;(e) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1674, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204;(f) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1200, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204;(g) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1661, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204;(h) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2323, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204; or(i) the variable heavy domain and the variable light domain comprise any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

91. The antibody of any one of claims 87-90, wherein:(a) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and (ii) the variableAttorney Docket No. 078306 / 636740 light domain compnses a v lCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; or(3) (i) the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2241. 2253, 2259, 1674, and 1200, and (ii) the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(b) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2241, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;Attorney Docket No. 078306 / 636740(c) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2253, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(d) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia. AbM. contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2259, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2243,Attorney Docket No. 078306 / 636740 or variants thereof in which an N -terminal glutamine or glutamate is replaced with pyroglutamate;(e) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO:

107. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1674, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; or(I) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; orAttorney Docket No. 078306 / 636740(3) (i) the variable heavy domain comprises the amino acid sequence SEQ ID NO: 1200, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 1204, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

92. The antibody of any one of claims 87-91, wherein the antibody is a chimeric or humanized antibody.

93. The antibody of any one of claims 87-92, wherein the antibody is an antigen-binding fragment of an intact antibody.

94. The antibody of any one of claims 87-92, wherein the antibody comprises a heavy chain constant domain and a light chain constant domain.

95. The antibody of claim 94, wherein:(a) the heavy chain constant domain comprise a set of heterodimerization skew variants; and / or(b) the heavy chain constant domain each comprise one or more ablation variants; and / or(c) the heavy chain constant domain comprises one or more pl variants.

96. The antibody of claim 94 or 95, wherein:(a) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering;(b) the heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering;(c) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering;(d) the heavy chain constant domain comprises amino acid substitutions L368D / K370S, wherein numbering is according to EU numbering;Attorney Docket No. 078306 / 636740(e) the heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(f) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(g) the heavy chain constant domain comprises amino acid substitutions E357Q / S364K, wherein numbering is according to EU numbering;(h) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering;(i) the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K, wherein numbering is according to Kabat numbering;(j) the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E, wherein numbering is according to Kabat numbering;(k) the heavy chain constant domain comprises amino acid substitution A141F and the light chain constant domain comprises amino acid substitution F 118A, wherein numbering is according to EU numbering;(l) the heavy chain constant domain comprises amino acid substitutions K213E / K218D and the light chain constant domain comprises amino acid substitutions D122K / E123K, wherein numbering is according to EU numbering;(m) the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering;(n) the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E according to Kabat numbering, andAttorney Docket No. 078306 / 636740 the heavy chain constant domain comprises ammo acid substitution A141F according to EU numbering and the light chain constant domain comprises amino acid substitution Fl 18A according to Kabat numbering;(o) the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, N208D / Q295E / N384D / Q418E / N421D, and K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering;(p) the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, E357Q / S364K, and A141F according to EU numbering and the light chain constant domain comprises amino acid substitution Fl 18A according to Kabat numbering; or(q) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, E357Q / S364K, and K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering.

97. The antibody of any one of claims 94-96, wherein the heavy chain constant domain is of isotype IgGl .

98. The antibody of any one of claims 87-90, wherein the antibody comprises a heavy chain and a light chain selected from the following:(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2240 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2242;Attorney Docket No. 078306 / 636740(b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2252 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2242;(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2258 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2242;(d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2265 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate;(e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2264 or a variant thereof in which the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2269 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate;(!) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2240, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242;(g) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2252, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242;(h) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2258, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2242;(i) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2265; orAttorney Docket No. 078306 / 636740(j) a heavy chain at least 90%. at least 95%. at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2264, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2269.

99. The antibody of any one of claims 87-98, wherein:(a) the antibody specifically binds human TL1 A with a KD of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance at 25°C, optionally wherein the antibody specifically binds human TL1A with a Ko of less than about 3E-11 M, less than about 2.9E-11 M, less than about 2.8E- 11 M, or less than about 2.7E-11 M; and / or(b) the antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an ICso of less than about 4.5 nM.

100. The antibody of any one of claims 87-99, wherein the antibody is a bispecific antibody or multispecific antibody.

101. The antibody of claim 100, wherein the bispecific antibody or multispecific antibody further comprises an interleukin-23 (IL23) antigen-binding domain.

102. The antibody of claim 100, wherein the bispecific antibody or multispecific antibody further comprises a means for binding IL23.

103. A pharmaceutical composition comprising the antibody of any one of claims 87-102 and a pharmaceutically acceptable carrier.

104. The pharmaceutical composition of claim 103. further comprising an antibody comprising an IL23 antigen-binding domain.

105. A kit comprising the antibody of any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104.Attorney Docket No. 078306 / 636740106. A vessel or delivery device comprising the antibody of any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104.

107. A nucleic acid composition comprising a nucleic acid or a set of nucleic acids encoding the antibody of any one of claims 87-102.

108. An expression vector composition an expression vector or a set of expression vectors comprising the nucleic acid composition of claim 107.

109. A host cell comprising the expression vector composition of claim 108.

110. A method of making an anti-TLl A antibody, comprising culturing the host cell of claim 109 under conditions wherein anti-TLl A antibody is expressed, and recovering the anti-TLl A antibody.

111. A method of inhibiting or reducing TL 1 A-mediated activity in a subject in need thereof, comprising administering to the subject the antibody of any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104.

112. An antibody according to any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104 for use in inhibiting or reducing TL1A- mediated activity in a subject in need thereof.

113. Use of an antibody according to any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104 for inhibiting or reducing TL1 A-mediated activity in a subject in need thereof.

114. Use of an antibody according to any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104 in the manufacture of a medicament for inhibiting or reducing TL1 A-mediated activity in a subject in need thereof.Attorney Docket No. 078306 / 636740115. A method of treating a TL1 A-associated disease in a subject in need thereof, comprising administering to the subject the antibody of any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104.

116. An antibody according to any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104 for use in the treatment of aTLl A- associated disease in a subject in need thereof.

117. Use of an antibody according to any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104 for the treatment of a TLl A-associated disease in a subject in need thereof.

118. Use of an antibody according to any one of claims 87-102 or the pharmaceutical composition of claim 103 or 104 in the manufacture of a medicament for the treatment of a TL1 A-associated disease in a subject in need thereof.

119. The method of claim 115, the antibody or the pharmaceutical composition for use of claim 116, or the use of claim 117 or 118, wherein the TL1A- associated disease is an inflammatory disease, an autoimmune disease, or a fibrotic disease, optionally wherein the TLlA-associated disease is an inflammatory bowel disease.

120. The method of any one of claims 111, 115, and 119, the antibody or the pharmaceutical composition for use of any one of claims 112. 116, and 119, or the use of any one of claims 113, 114, and 117-119, wherein the subject is a human.

121. The antibody or the pharmaceutical composition for use of any one of claims 112, 116, 119, and 120. or the use of any one of claims 113, 114, and 117-120, wherein the antibody comprising the TLlA-antigen binding domain is used in combination with an antibody comprising an IL23 antigen-binding domain.

122. The method of any one of claims 111, 115, 119, and 120, further comprising administering an antibody comprising an IL23 antigen-binding domain.Attorney Docket No. 078306 / 636740123. The antibody or the pharmaceutical composition for use of claim 121. the use of claim 121, or the method of claim 122, wherein the antibody comprising the IL23 antigen-binding domain and the antibody comprising the TL1 A antigen-binding domain are administered simultaneously.

124. The antibody for use of claim 121, the use of claim 121, or the method of claim 122, wherein the antibody comprising the IL23 antigen-binding domain and the antibody comprising the TL1A antigen-binding domain are administered sequentially in any order.

125. An antibody comprising an interleukin-23 (IL23) antigen-binding domain comprising a variable heavy domain and a variable light domain selected from the following sets of variable heavy domains and variable light domains:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248;(b) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237;(d) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248;Attorney Docket No. 078306 / 636740(e) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231;(f) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248; and(g) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387. XENP53415. XENP53370, XENP53371 , XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition.

126. The antibody of claim 125, wherein:(a) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;(b) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;Attorney Docket No. 078306 / 636740(c) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250: or(d) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.

127. The antibody of claim 125 or 126, wherein:(a) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248;(b) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234;(c) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%. at least 98%. or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237;(d) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248;(e) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO: 2113, and the variable light domain is at least 90%, at least 95%, at least 96%. at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231;(f) the variable heavy domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and the variable light domain is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248; or(g) the variable heavy domain and the variable light domain are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

128. The antibody of any one of claims 125-127, wherein:(a) the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248;(b) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2233, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2234;(c) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2235, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2237;(d) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 179, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1248;(e) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2113, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 2231;(!) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 1967, and the variable light domain comprises the amino acid sequence of SEQ ID NO: 1248; orAttorney Docket No. 078306 / 636740(g) the variable heavy domain and the variable light domain comprise any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379. XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

129. The antibody of any one of claims 125-128, wherein:(a) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234. 2237, and 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the variable heavy domain comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (ii) the variable light domain comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(b) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acidAttorney Docket No. 078306 / 636740 sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250: or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2233, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(c) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (ii) the variable light domain comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236. and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 2235, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; or(d) (1) (i) the variable heavy domain comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (ii) the variable light domain comprises a vlCDRl, aAttorney Docket No. 078306 / 636740 vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the variable heavy domain comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (ii) the variable light domain comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the variable heavy domain comprises the amino acid sequence of SEQ ID NO: 179, and (ii) the variable light domain comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

130. The antibody of any one of claims 125-129, wherein the antibody is a chimeric or humanized antibody.131 . The antibody of any one of claims 125-130, wherein the antibody is an antigen-binding fragment of an intact antibody.

132. The antibody of any one of claims 125-130, wherein the antibody comprises a heavy chain constant domain and a light chain constant domain.

133. The antibody of claim 132, wherein:(a) the heavy chain constant domain comprise a set of heterodimerization skew variants; and / or(b) the heavy chain constant domain each comprise one or more ablation variants; and / or(c) the heavy chain constant domain comprises one or more pl variants.

134. The antibody of claim 132 or 133, wherein:Attorney Docket No. 078306 / 636740(a) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering;(b) the heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering;(c) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering;(d) the heavy chain constant domain comprises amino acid substitutions L368D / K370S. wherein numbering is according to EU numbering;(e) the heavy chain constant domain comprises amino acid substitutions N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(f) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, and N208D / Q295E / N384D / Q418E / N421D, wherein numbering is according to EU numbering;(g) the heavy chain constant domain comprises amino acid substitutions E357Q / S364K. wherein numbering is according to EU numbering;(h) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, and E357Q / S364K, wherein numbering is according to EU numbering;(i) the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K, wherein numbering is according to Kabat numbering;(j) the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E, wherein numbering is according to Kabat numbering;(k) the heavy chain constant domain comprises amino acid substitution A141F and the light chain constant domain comprises amino acid substitution F 118A, wherein numbering is according to EU numbering;(l) the heavy chain constant domain comprises amino acid substitutions K213E / K218D and the light chain constant domain comprises amino acid substitutions D122K / E123K, wherein numbering is according to EU numbering;Attorney Docket No. 078306 / 636740(m) the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering;(n) the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitution A141F according to EU numbering and the light chain constant domain comprises amino acid substitution Fl 18A according to Kabat numbering;(o) the variable heavy domain comprises amino acid substitution Q39E and the variable light domain comprises amino acid substitution Q38K according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, L368D / K370S, N208D / Q295E / N384D / Q418E / N421D, and K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering;(p) the variable heavy domain comprises amino acid substitution Q39K and the variable light domain comprises amino acid substitution Q38E according to Kabat numbering, and the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, E357Q / S364K, and A141F according to EU numbering and the light chain constant domain comprises amino acid substitution F118A according to Kabat numbering; or(q) the heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, M428L / N434S, E357Q / S364K, and K213E / K218D according to EU numbering and the light chain constant domain comprises amino acid substitutions D122K / E123K according to Kabat numbering.Attorney Docket No. 078306 / 636740135. The antibody of any one of claims 132-134, wherein the heavy chain constant domain is of isotype IgGl .

136. The antibody of any one of claims 125-128, wherein the antibody comprises a heavy chain and a light chain selected from the following:(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2244 or a variant thereof in which the N-terminal glutamine is replaced w ith pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2245;(b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2250 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2251;(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2266 or a variant thereof in which the N-terminal glutamine is replaced with pyroglutamate and / or the C-terminal lysine or the C-terminal lysine and glycine are removed, and a light chain comprising the amino acid sequence of SEQ ID NO: 2267;(d) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2244, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2245;(e) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2250, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2251; or(f) a heavy chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2266, and a light chain at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2267.

137. The antibody of any one of claims 125-136, wherein:(a) the antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance at 25°C, optionally wherein theAttorney Docket No. 078306 / 636740 antibody specifically binds human 1L23 with a KD of less than about 6E-11 M. less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M; and / or(b) the antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the antibody inhibits IL23 activity with an IC50 of less than about 60 pM. less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

138. The antibody of any one of claims 125-137, wherein the antibody is a bispecific antibody or multispecific antibody.

139. The antibody of claim 138, wherein the bispecific antibody or multispecific antibody further comprises a TNF-like ligand 1A (TL1A) antigen-binding domain.

140. The antibody of claim 138, wherein the bispecific antibody or multispecific antibody further comprises a means for binding TL1 A.141 . A pharmaceutical composition comprising the antibody of any one of claims 125-140 and a pharmaceutically acceptable carrier.

142. The pharmaceutical composition of claim 141, further comprising an antibody comprising an TL1 A antigen-binding domain.

143. A kit comprising the antibody of any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142.

144. A vessel or delivery device comprising the antibody of any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142.

145. A nucleic acid composition comprising a nucleic acid or a set of nucleic acids encoding the antibody of any one of claims 125-140.Attorney Docket No. 078306 / 636740146. An expression vector composition an expression vector or a set of expression vectors comprising the nucleic acid composition of claim 145.

147. Ahost cell comprising the expression vector composition of claim 146.

148. A method of making an anti-IL23 antibody, comprising culturing the host cell of claim 147 under conditions wherein anti-IL23 antibody is expressed, and recovering the anti-IL23 antibody.

149. A method of inhibiting or reducing IL23-mediated activity in a subject in need thereof, comprising administering to the subject the antibody of any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142.

150. An antibody according to any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142 for use in inhibiting or reducing 1L23- mediated activity in a subj ect in need thereof.

151. Use of an antibody according to any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142 for inhibiting or reducing IL23-mediated activity' in a subject in need thereof.

152. Use of an antibody according to any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142 in the manufacture of a medicament for inhibiting or reducing IL23-mediated activity in a subject in need thereof.

153. Amethod of treating an IL23-associated disease in a subject in need thereof, comprising administering to the subject the antibody of any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142.

154. An antibody according to any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142 for use in the treatment of an IL23- associated disease in a subject in need thereof.Attorney Docket No. 078306 / 636740155. Use of an antibody according to any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142 for the treatment of an IL23-associated disease in a subject in need thereof.

156. Use of an antibody according to any one of claims 125-140 or the pharmaceutical composition of claim 141 or 142 in the manufacture of a medicament for the treatment of an IL23-associated disease in a subject in need thereof.

157. The method of claim 153, the antibody or the pharmaceutical composition for use of claim 154, or the use of claim 155 or 156, wherein the IL23-associated disease is an inflammatory disease, an autoimmune disease, or a fibrotic disease, optionally wherein the IL23-associated disease is an inflammatory bowel disease.

158. The method of any one of claims 149, 153. and 157. the antibody or the pharmaceutical composition for use of any one of claims 150, 154, and 157, or the use of any one of claims 151, 152, and 155-157, wherein the subject is a human.

159. The antibody or the pharmaceutical composition for use of any one of claims 150, 154, 157, and 158, or the use of any one of claims 151, 152, and 155-158, wherein the antibody comprising the IL23-antigen binding domain is used in combination with an antibody comprising an TL1A antigen-binding domain.

160. The method of any one of claims 149, 153. 157, and 158, further comprising administering an antibody comprising an TL1 A antigen-binding domain.

161. The antibody for use of claim 159, the use of claim 159, or the method of claim 160. wherein the antibody comprising the TL1 A antigen-binding domain and the antibody comprising the IL23 antigen-binding domain are administered simultaneously.

162. The antibody for use of claim 159, the use of claim 159, or the method of claim 160. wherein the antibody comprising the TL1 A antigen-binding domain and the antibody comprising the IL23 antigen-binding domain are administered sequentially in any order.Attorney Docket No. 078306 / 636740163. A combination comprising:(a) a first antibody comprising a TNF-like ligand 1 A (TL1 A) antigenbinding domain comprising a variable heavy domain (VH1) and a variable light domain (VL1); and(b) a second antibody comprising an interleukin-23 (IL23) antigen-binding domain comprising a variable heavy domain (VH2) and a variable light domain (VL2).

164. The combination of claim 163, wherein:(a) the VH1 and VL1 are selected from:(1) (i) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLIA variable heavy domain and variable light domain in Table 44, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(ii) a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLIA variable heavy domain and variable light domain in Tables 7-10, 22, 23, 26, 29-34, and 48, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; and(iii) a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of 1824-1923, optionally wherein the CDRs are as defined by the Kabat. Chothia, Kabat + Chothia. AbM, contact, or IMGT definition;(2) (i) any pair of anti-TLIA variable heavy domain and variable light domain in Table 44; and(ii) any pair of anti-TLIA variable heavy domain and variable light domain in Tables 7-10, 22, 23, 26. 29-34, and 48; andAttorney Docket No. 078306 / 636740(iii) a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 1427-1823 and 2316-2330, and a variable light domain comprising the amino acid sequence of any one of 1824-1923, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; and / or(b) the VH2 and VL2 are selected from:(1) (i) a variable heavy domain comprising a vhCDRl, a vhCDR2. and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Table 44, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(ii) a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in Tables 1 1, 24-26, 29-34, and 49, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition;(iii) a variable heavy domain comprising a vhCDRl , a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of 1927-2132, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of 2133-2232, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition;(2) (i) any pair of anti-lL23 variable heavy domain and variable light domain in Table 44; and(ii) any pair of anti-IL23 variable heavy domain and variable light domain in Tables 11, 24-26, 29-34, and 49; and(iii) a variable heavy domain comprising the amino acid sequence of any one of 1927-2132, and a variable light domain comprising the amino acid sequence of any one of 2133-2232, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.Attorney Docket No. 078306 / 636740165. The combination of claim 163. wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259. 1674, and 1200, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(d) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243;(e) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(f) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;Attorney Docket No. 078306 / 636740(g) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1661, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(h) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2323. and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204;(i) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 101, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1 5; and(j) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within any pair of anti-TLl A variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM. contact, or IMGT definition.

166. The combination of claim 163, wherein the VH1 and the VL1 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;Attorney Docket No. 078306 / 636740(b) a vanable heavy domain comprising a vhCDRl comprising the ammo acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203. and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108;(e) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1926, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

106. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108; and(f) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 103, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108.

167. The combination of any one of claims 163-166, wherein:Attorney Docket No. 078306 / 636740(a) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2241, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(c) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2253, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(d) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2259, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2243;(e) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1674, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(I) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1200, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(g) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1661, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2323, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1204;Attorney Docket No. 078306 / 636740(i) the VH1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 101, and the VL1 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 105; or(j) the VH1 and the VL1 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-TLIA variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

168. The combination of claim 163, wherein:(a) the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674. and 1200, and the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204;(b) the VH1 comprises the amino acid sequence of SEQ ID NO: 2241, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(c) the VH1 comprises the amino acid sequence of SEQ ID NO: 2253, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(d) the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, and the VL1 comprises the amino acid sequence of SEQ ID NO: 2243;(e) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(f) the VH1 comprises the amino acid sequence of SEQ ID NO: 1200, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(g) the VH1 comprises the amino acid sequence of SEQ ID NO: 1661, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(h) the VH1 comprises the amino acid sequence of SEQ ID NO: 2323, and the VL1 comprises the amino acid sequence of SEQ ID NO: 1204;(i) the VH1 comprises the amino acid sequence of SEQ ID NO: 101, and the VL1 comprises the amino acid sequence of SEQ ID NO: 105; or(j) the VH1 and the VL1 comprise any pair of anti-TLIA variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375,Attorney Docket No. 078306 / 636740XENP53387, XENP53415, XENP53370, XENP5337E XENP53376. XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

169. The combination of any one of claims 163-168, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248;(b) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234;(c) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237;(d) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248;(e) a variable heavy domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2113, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2231;Attorney Docket No. 078306 / 636740(f) a vanable heavy domain comprising a vhCDRl. a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1967, and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248; and(g) a variable heavy' domain comprising a vhCDRl, a vhCDR2, and a vhCDR3 and a variable light domain comprising a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable heavy domain and variable light domain pair in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415. XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition.

170. The combination of any one of claims 163-168, wherein the VH2 and the VL2 are selected from the following:(a) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;(b) a vanable heavy' domain comprising a vhCDRl comprising the ammo acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250;(c) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ IDAttorney Docket No. 078306 / 636740NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250: and(d) a variable heavy domain comprising a vhCDRl comprising the amino acid sequence of SEQ ID NO: 2239, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and a variable light domain comprising a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250.171 . The combination of any one of claims 163-170, wherein:(a) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS:2233, 2235, and 179, and the VL2 is at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOS:2234, 2237, and 1248;(b) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2233, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2234;(c) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2235, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2237;(d) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 179, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248;(e) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2113, and the VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2231;(1) the VH2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1967, and theAttorney Docket No. 078306 / 636740VL2 is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any pair of anti-IL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375. XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414.

172. The combination of any one of claims 163-168, wherein:(a) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248;(b) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2234;(c) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2237;(d) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248;(e) the VH2 comprises the amino acid sequence of SEQ ID NO: 2113, and the VL2 comprises the amino acid sequence of SEQ ID NO: 2231;(I) the VH2 comprises the amino acid sequence of SEQ ID NO: 1967, and the VL2 comprises the amino acid sequence of SEQ ID NO: 1248; or(g) the VH2 and the VL2 comprise any pair of anti-lL23 variable heavy domain and variable light domain in XENP53412, XENP53413, XENP53369, XENP53375, XENP53387, XENP53415, XENP53370, XENP53371, XENP53376, XENP53377, XENP53378, XENP53379, XENP53380, or XENP53414, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

173. The combination of any one of claims 163-172, wherein:(a) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2241, 2253, 2259, 1674, and 1200, (n) the VL1 compnses a vlCDRl, aAttorney Docket No. 078306 / 636740 vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2. and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102 or 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924 or 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO:

107. and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182 or 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249 or 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of any one of SEQ ID NOS: 2241, 2253. 2259, 1674, and 1200, (ii) the VL1 comprises the amino acid sequence of any one of SEQ ID NOS: 2243 and 1204. (iii) the VH2 comprises the amino acid sequence of any one of SEQ ID NOS: 2233, 2235, and 179, and (iv) the VL2 comprises the amino acid sequence of any one of SEQ ID NOS: 2234, 2237, and 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(b) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243. (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2Attorney Docket No. 078306 / 636740 comprises a vlCDRl, a vlCDR2. and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO:

102. a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH 1 comprises the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(c) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2241, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2235, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2237; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprisingAttorney Docket No. 078306 / 636740 the amino acid sequence of SEQ ID NO:

108. (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 2236, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 2238, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250: or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO:2241, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2235. and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2237, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(d) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2253, (ii) the VL1 comprises a vlCDRl , a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the ammo acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO:

184. a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; orAttorney Docket No. 078306 / 636740(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO:2253, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;(e) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 2234, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 104, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO:

181. and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 2259, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 2243, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 2233, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 2234, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate;Attorney Docket No. 078306 / 636740(f) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 102, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1924, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence of SEQ ID NO: 1674, (ii) the VL1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate; or(g) (1) (i) the VH1 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 1200, (ii) the VL1 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises a vhCDRl, a vhCDR2, and a vhCDR3 contained within a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises a vlCDRl, a vlCDR2, and a vlCDR3 contained within a variable light domain comprising theAttorney Docket No. 078306 / 636740 amino acid sequence of SEQ ID NO: 1248, optionally wherein the CDRs are as defined by the Kabat, Chothia, Kabat + Chothia, AbM, contact, or IMGT definition; or(2) (i) the VH1 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 1201, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 1202, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO: 1203, (ii) the VL1 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 106, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 108, (iii) the VH2 comprises a vhCDRl comprising the amino acid sequence of SEQ ID NO: 180, a vhCDR2 comprising the amino acid sequence of SEQ ID NO: 181, and a vhCDR3 comprising the amino acid sequence of SEQ ID NO:182, and (iv) the VL2 comprises a vlCDRl comprising the amino acid sequence of SEQ ID NO: 184, a vlCDR2 comprising the amino acid sequence of SEQ ID NO: 1249, and a vlCDR3 comprising the amino acid sequence of SEQ ID NO: 1250; or(3) (i) the VH1 comprises the amino acid sequence SEQ ID NO: 1200, (ii) the VL 1 comprises the amino acid sequence of SEQ ID NO: 1204, (iii) the VH2 comprises the amino acid sequence of SEQ ID NO: 179, and (iv) the VL2 comprises the amino acid sequence of SEQ ID NO: 1248, or variants thereof in which an N-terminal glutamine or glutamate is replaced with pyroglutamate.

174. The combination of any one of claims 163-173, wherein the first antibody comprises (i) a first heavy chain comprising the VH1 and a first heavy’ chain constant domain, and (ii) a first light chain comprising the VL1 and a first light chain constant domain, and wherein the second antibody comprises (iii) a second heavy chain comprising the VH2 and a second heavy chain constant domain, and (iv) a second light chain comprising the VL2 and a second light chain constant domain.

175. The combination of claim 174, wherein:(a) the first heavy chain constant domain and the second heavy chain constant domain each comprise one or more ablation variants; and / or(b) the first heavy chain constant domain or the second heavy chain constant domain comprises one or more pl variants.Attorney Docket No. 078306 / 636740176. The combination of claim 174 or 175, wherein:(a) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K, wherein numbering is according to EU numbering;(b) the first heavy chain constant domain comprises amino acid substitutions M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions M428L / N434S, wherein numbering is according to EU numbering; or(c) the first heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S and / or the second heavy chain constant domain comprises amino acid substitutions E233P / L234V / L235A / G236del / S267K and M428L / N434S, wherein numbering is according to EU numbering.

177. The combination of any one of claims 174-176, wherein the first heavy chain constant domain is of isotype IgGl, and / or the second heavy chain constant domain is of isotype IgGl.

178. The combination of any one of claims 163-177, wherein the first antibody is a chimeric or humanized antibody, and / or the second antibody is a chimeric or humanized antibody.

179. The combination of any one of claims 163-178, wherein:(a) the first antibody specifically binds human TL1 A with a D of less than about 6.5E-11 M, less than about 6.4 E-ll M, or less than about 6.3E-11 as measured by surface plasmon resonance at 25°C, optionally wherein the first antibody specifically binds human TL1 A with a Ko of less than about 3E-11 M. less than about 2.9E-11 M, less than about 2.8E-11 M, or less than about 2.7E-11 M; and / or(b) the first antibody inhibits TL1 A activity in a TL1 A luciferase reporter assay with an IC50 of less than about 4.5 nM; and / or(c) the second antibody specifically binds human IL23 with a KD of less than about 1.1E-10 M as measured by surface plasmon resonance at 25°C, optionally whereinAttorney Docket No. 078306 / 636740 the second antibody specifically binds human IL23 with a KD of less than about 6E-11 M, less than about 5.9E-11 M, less than about 5.8E-11 M, or less than about 5.7E-11 M; and / or(d) the second antibody inhibits IL23 activity in an IL23 luciferase reporter assay with an IC50 of less than about 65 pM, less than about 64 pM, or less than about 63 pM, optionally wherein the second antibody inhibits IL23 activity with an IC50 of less than about 60 pM, less than about 59 pM, less than about 58 pM, less than about 57 pM, or less than about 56 pM.

180. A pharmaceutical composition comprising the combination of any one of claims 163-179 and a pharmaceutically acceptable carrier.

181. A kit comprising the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180.

182. A vessel or delivery device comprising the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180.

183. A nucleic acid composition comprising a nucleic acid or a set of nucleic acids encoding the combination of any one of claims 163-179.

184. An expression vector composition comprising an expression vector or a set of expression vectors comprising the nucleic acid composition of claim 183.

185. A method of inhibiting or reducing TL 1 A-mediated activity and / or IL23-mediated activity' in a subject in need thereof, comprising administering to the subject the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180.

186. The combination of any one of claims 163-179 or the pharmaceutical composition of claim 180 for use in inhibiting or reducing TLlA-mediated activity and / or IL23-mediated activity in a subject in need thereof.Attorney Docket No. 078306 / 636740187. Use of the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180 for inhibiting or reducing TLlA-mediated activity and / or IL23-mediated activity in a subject in need thereof.

188. Use of the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180 in the manufacture of a medicament for inhibiting or reducing TL1 A-mediated activity and / or IL23 -mediated activity in a subject in need thereof.

189. A method of treating a TL1 A-associated disease and / or IL23- associated disease in a subject in need thereof, comprising administering to the subject the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180.

190. The combination of any one of claims 163-179 or the pharmaceutical composition of claim 180 for use in the treatment of a TL 1 A-associated disease and / or IL23- associated disease in a subject in need thereof.

191. Use of the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180 for the treatment of a TL1 A-associated disease and / or IL23-associated disease in a subject in need thereof.

192. Use of the combination of any one of claims 163-179 or the pharmaceutical composition of claim 180 in the manufacture of a medicament for the treatment of a TL1 A-associated disease and / or IL23-associated disease in a subject in need thereof.

193. The method of claim 189, the combination or the pharmaceutical composition for use of claim 190, or the use of claim 191 or 192, wherein the TL1A- associated disease and / or IL23-associated disease is an inflammatory disease, an autoimmune disease, or a fibrotic disease, optionally wherein the TL1 A-associated disease and / or IL23- associated disease is an inflammatory bowel disease.Attorney Docket No. 078306 / 636740194. The method of any one of claims 185, 189. and 193. the combination or the pharmaceutical composition for use of any one of claims 186, 190, and 193, or the use of any one of claims 187, 188, and 191-193, wherein the subject is a human.

195. A heterodimeric antibody comprising:(a) a first monomer comprising: (i) a single chain variable fragment (scFv); and (ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;(b) a second monomer comprising, from N-terminal to C-terminal, a VH1 - CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a second Fc domain; and(c) a light chain comprising, from N-terminal to C- terminal, VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain, wherein the scFv comprises a second VH domain (VH2), a scFv linker, and a second variable light domain (VL2), wherein the VH1 and the VL1 together form a first antigen-binding domain (ABD) and the VH2 and the VL2 together form a second ABD, and wherein one of the first ABD and second ABD is a TL1 A binding domain and the other of the first ABD and second ABD is an IL23 binding domain.

196. A heterodimeric antibody comprising:(a) a first monomer comprising a VHl-CHl-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a first Fc domain;(b) a second monomer comprising a VH2-CHl-hinge-CH2-CH3, w herein VH2 is a second variable heavy domain and CH2-CH3 is a second Fc domain;(c) a first common light chain comprising a VL-CL; and(d) a second common light chain comprising a VL-CL, wherein the VH1 and the VL of the first common light chain together form a first antigen-binding domain (ABD) and the VH2 and the VL of the second common light chain together form a second ABD.

197. A heterodimeric antibody comprising:Attorney Docket No. 078306 / 636740(a) a first monomer comprising: (i) a VHl-CHl-hinge-CH2-CH3. and (ii) a first scFv comprising a VH2-scFv linker-VL2, wherein the scFv is covalently attached to the CH3 of the first monomer by a linker;(b) a second monomer comprising: (i) a VHl-CHl-hinge-CH2-CH3, and(ii) a second scFv comprising a VH2-scFv linker-VL2, wherein the scFv is covalently attached to the CH3 of the second monomer by a linker;(c) a first light chain comprising a VL1-CL; and(d) a second light chain comprising a VL 1 -CL, wherein each of the VHls of the first monomer and second monomer are a first variable heavy domain, each of the VLls of the first monomer and second monomer are a first light domain, each of the VH2s are a second variable heavy domain, and each of the VL2s are a second variable light domain, where the VH1 of the first monomer and VL1 of the first light chain, and the VH1 of the second monomer and VL1 of the second light chain each form a first antigenbinding domain, and the VH2 and VL2 of the first and second scFvs each for a second antigen-binding domain, wherein the first ABDs or the second ABDs are TL1 A binding domains and the other of the first ABDs and second ABDs are IL23 binding domains.

Images